<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">TAK</journal-id>
<journal-id journal-id-type="hwp">sptak</journal-id>
<journal-id journal-id-type="nlm-ta">Ther Adv Cardiovasc Dis</journal-id>
<journal-title>Therapeutic Advances in Cardiovascular Disease</journal-title>
<issn pub-type="ppub">1753-9447</issn>
<issn pub-type="epub">1753-9455</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1753944713477518</article-id>
<article-id pub-id-type="publisher-id">10.1177_1753944713477518</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Management of pulmonary hypertension in left heart disease</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name><surname>Schmeisser</surname><given-names>Alexander</given-names></name>
<aff id="aff1-1753944713477518">Internal Medicine/Cardiology, Angiology and Pneumology, Magdeburg University, Leipziger Str.44, 39120 Magdeburg, Germany</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Schroetter</surname><given-names>Hagen</given-names></name>
<aff id="aff2-1753944713477518">Technical University Dresden, Heart Centre Dresden, University Hospital, Department of Internal Medicine and Cardiology, Dresden, Germany</aff>
</contrib>
<contrib contrib-type="author">
<name><surname>Braun-Dulleaus</surname><given-names>Ruediger C.</given-names></name>
<aff id="aff3-1753944713477518">Internal Medicine/Cardiology, Angiology and Pneumology, Magdeburg University, Magdeburg, Germany</aff>
</contrib>
</contrib-group>
<author-notes>
<corresp id="corresp1-1753944713477518"><email>Alexander.Schmeisser@med.ovgu.de</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2013</year>
</pub-date>
<volume>7</volume>
<issue>3</issue>
<fpage>131</fpage>
<lpage>151</lpage>
<permissions>
<copyright-statement>© The Author(s), 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Pulmonary hypertension (PH) due to left heart disease is classified as group II according to the Dana Point classification, which includes left ventricular systolic and/or diastolic left heart failure, and left-sided valvular disease. PH due to left heart disease is the most common cause and when present, especially with right ventricular dysfunction, is associated with a worse prognosis. Left heart disease with secondary PH is associated with increased left atrial pressure, which causes a passive increase in pulmonary pressure. Passive PH could be superimposed by an active protective, and in some patients by an ‘out of proportion’, elevated precapillary pulmonary vasoconstriction and vascular remodelling which leads to greater or lesser further increase of the pulmonary artery pressure. In this review, epidemiological and pathophysiologic mechanisms for the development of group II PH are summarized. The conflicting data about the haemodynamic and possible parameters to diagnose passive versus reactive and ‘out of proportion’ PH are presented. The different therapeutic concepts, along with novel treatment strategies, are reviewed in detail and critically discussed regarding their effectiveness and safety.</p>
</abstract>
<kwd-group>
<kwd>pulmonary hypertension due to left heart disease</kwd>
<kwd>transpulmonary gradient</kwd>
<kwd>post-capillary pulmonary hypertension</kwd>
<kwd>management</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1753944713477518" sec-type="intro">
<title>Introduction</title>
<p>Pulmonary hypertension (PH), any condition with a mean pulmonary pressure ≥25 mmHg at rest, is currently classified into five different groups. International meetings on PH in the past have focused predominantly on pulmonary arterial hypertension (PAH; Group I), with the result that enormous progress has been achieved in the pathophysiology and therapy of PAH patients. The 4th World Symposium was the first to assign a working group to address in detail the so-called non-PAH forms of PH, that is, those forms of PH encountered in patients with left heart disease (Group II), with chronic obstructive disease (COPD) and interstitial lung disease (Group III), venous thromboembolism (Group IV) and other conditions (Group V) [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr63-1753944713477518">Hoeper <italic>et al</italic>. 2009</xref>].</p>
<p>In this review, we focus on PH due to left heart disease as the perhaps most common PH scenario. We present an overview on the pathophysiology, natural history, clinical signs and treatment of PH in left heart disease.</p>
</sec>
<sec id="section2-1753944713477518">
<title>PH due to left heart disease as a postcapillary PH</title>
<p>The elevated pulmonary vascular resistance in PH patients of groups I, III, IV and V originates from the precapillary regions of the pulmonary vascular system. Different pathological entities are found within the distal pulmonary arteries, including intimal proliferative, fibrotic and thrombotic lesions, as well as inflammatory infiltrates. Pulmonary veins are predominantly unaffected [<xref ref-type="bibr" rid="bibr63-1753944713477518">Hoeper <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr112-1753944713477518">Simonneau <italic>et al</italic>. 2004</xref>]. According to the haemodynamic definitions of PH, such patients are characterized by a mean pulmonary arterial pressure (PAP) ≥25 mmHg with classically normal left ventricular filling and left atrial pressures [pulmonary capillary wedge pressure (PCWP) ≤15 mmHg], resulting in an elevated transpulmonary gradient [TPG = PAPmean – mean pulmonary wedge pressure (PCWPmean) (<xref ref-type="fig" rid="fig1-1753944713477518">Figure 1</xref>).</p>
<fig id="fig1-1753944713477518" position="float">
<label>Figure 1.</label>
<caption>
<p>Haemodynamic definition of pulmonary hypertension (ESC guidelines) [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>].</p>
<p>  Group I: pulmonary arterial hypertension (PAH)</p>
<p>  Group II: pulmonary hypertension (PH) associated with left heart disease</p>
<p>  Group III: PH associated with chronic lung disease</p>
<p>  Group IV: chronic thromboembolic PH (CTEPH)</p>
<p>  Group V: PH with unclear multifactorial mechanisms</p>
<p>ESC: European Society of Cardiology; LAP: left atrial pressure; PCWP: pulmonary capillary wedge pressure; TPG: transpulmonary gradient.</p>
</caption>
<graphic xlink:href="10.1177_1753944713477518-fig1.tif"/>
</fig>
<p>In contrast, PH due to left heart disease has been defined as a postcapillary form of PH. In the original nomenclature from 1998, this form of PH had been classified as secondary PH or ‘pulmonary venous hypertension’ to indicate that the elevation of the PAP is solely the consequence of increased pressure within the left atrium and pulmonary veins (PWP ≥15 mmHg) and of a low pressure transpulmonary gradient within normal range (5–9 mmHg) [<xref ref-type="bibr" rid="bibr47-1753944713477518">Guazzi and Arena, 2010</xref>]. A reduction in PAPmean is strongly dependent on a PCWP reduction, which implies that left atrial pressure largely determines the pulmonary artery pressure in left heart disease. In the case of a normal range TPG, no component of the PH is derived from abnormalities intrinsic to the pulmonary arterial bed. Therefore, left-sided PH in this stage has been defined as a passive PH [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr47-1753944713477518">Guazzi and Arena, 2010</xref>; <xref ref-type="bibr" rid="bibr112-1753944713477518">Simonneau <italic>et al</italic>. 2004</xref>].</p>
</sec>
<sec id="section3-1753944713477518">
<title>Passive <italic>versus</italic> reactive PH due to left heart disease</title>
<p>Haemodynamic studies from patients with left heart disease confirm the high correlation between increased and elevated left atrial pressure (PCWP) and the resulting mean pulmonary arterial pressure [<xref ref-type="bibr" rid="bibr33-1753944713477518">Drazner <italic>et al</italic>. 1999</xref>; <xref ref-type="bibr" rid="bibr65-1753944713477518">Ilsar <italic>et al</italic>. 2010</xref>]. However, a wide scattering of values along the correlation line has been appreciated. We have observed in 120 patients with advanced systolic heart failure that the same PCWP may have very different TPGs, resulting in different PAP [H. Schroetter <italic>A. Schmeisser, R. Strasser and R. Braun-Dulleaus.</italic> Personal communication (unpublished results)] (<xref ref-type="fig" rid="fig2-1753944713477518">Figure 2</xref>). This implies that, in the case of elevated TPGs, a reactive precapillary component of pressure elevation is added to the passive transmission of the left atrial pressure. At this stage of a reactive PH, both functional and structural abnormalities of the pulmonary arterial bed are presumed [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr63-1753944713477518">Hoeper <italic>et al</italic>. 2009</xref>].</p>
<fig id="fig2-1753944713477518" position="float">
<label>Figure 2.</label>
<caption>
<p>Correlation of TPG with PCWPmean in patients with advanced systolic heart failure.</p>
<p>A wide scattering of the data along the correlation line could be demonstrated. This means patients with the same PCWP may have very different TPGs, which results in different pulmonary artery pressures. <italic>n</italic> = 120 patients with advanced systolic heart failure [H. Schroetter A. Schmeisser, R. Strasser and R. Braun-Dullaeus. Personal communication (unpublished results)]</p>
<p>PAP: pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; TPG: transpulmonary gradient.</p>
</caption>
<graphic xlink:href="10.1177_1753944713477518-fig2.tif"/>
</fig>
</sec>
<sec id="section4-1753944713477518">
<title>Functional and structural pathology in reactive PH</title>
<p>The endothelium-mediated local control of vasomotility in healthy individuals is primarily based on a balanced release of nitric oxide (NO) and endothelin-1 (ET-1) [<xref ref-type="bibr" rid="bibr17-1753944713477518">Budhiraja <italic>et al</italic>. 2004</xref>]. The imbalance of these two opposing systems is suggested in patients with left heart disease and PH resulting in an increased resistive pulmonary arterial tone [<xref ref-type="bibr" rid="bibr45-1753944713477518">Giaid <italic>et al</italic>. 1993</xref>; <xref ref-type="bibr" rid="bibr44-1753944713477518">Giaid and Saleh, 1995</xref>]. Human and animal studies demonstrated a lack of NO synthesis in response to mechanical or receptor-mediated stimulation in lung venous capillaries and small arterioles in group II PH [<xref ref-type="bibr" rid="bibr25-1753944713477518">Cooper <italic>et al</italic>. 1998</xref>]. In addition, recent data from a rat model of congestive heart failure could identify an impaired endothelial Ca<sup>2+</sup> signalling and NO synthesis caused by an extensive cytoskeletal reorganization in lung endothelial cells [<xref ref-type="bibr" rid="bibr70-1753944713477518">Kerem <italic>et al</italic>. 2010</xref>]. In contrast, increased endothelial cell expression and elevated plasma levels of the very potent vasoconstrictor ET-1 and its increased lung endothelial cell expression have been shown in experimental models and human patients with heart failure [<xref ref-type="bibr" rid="bibr24-1753944713477518">Cody <italic>et al</italic>. 1992</xref>].</p>
<p>Furthermore, an elevated pulmonary precapillary tone as a functional abnormality in a large number of patients with left heart disease is also associated with a morphological remodelling of the distal pulmonary arteries, the capillaries, the venous bed and the alveoles. Acutely or chronically increased left atrial pressure may lead to alveolar stress failure, a process that disrupts the functional properties of the alveolar capillaries. While acute stress failure is a reversible phenomenon, the alveolar capillary membrane undergoes a remodelling process during chronic capillary pressure elevation that eventually is not reversible [<xref ref-type="bibr" rid="bibr47-1753944713477518">Guazzi and Arena, 2010</xref>].</p>
<p>In chronic PH, a superimposition of additional factors other than mechanical stress, such as neurohormonal, cytotoxic, hypoxic and genetic factors, further injure lung capillaries and alveolar spaces, which triggers a process of alveolar remodelling that ultimately leads to gas exchange impairment [<xref ref-type="bibr" rid="bibr17-1753944713477518">Budhiraja <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr30-1753944713477518">De Vita <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr52-1753944713477518">Guazzi <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr47-1753944713477518">Guazzi and Arena, 2010</xref>]. Enlarged and thickened pulmonary veins, dilatation of pulmonary capillaries, enlarged lymphatic vessels, muscularization, and perivascular fibrosis of the arterioles are morphological changes of this type of PH [<xref ref-type="bibr" rid="bibr23-1753944713477518">Chen <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr29-1753944713477518">Delgado <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr52-1753944713477518">Guazzi <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr122-1753944713477518">Yin <italic>et al</italic>. 2011</xref>].</p>
<p>The degree of change in vessel structure and vascular resistance varies widely, which implies that the natural evolution of PH is very different across the spectrum of patients with group II PH. The most severe histological changes have been reported in patients with mitral stenosis with substantially increased systolic and diastolic left atrial pressure over a long time period [<xref ref-type="bibr" rid="bibr115-1753944713477518">Tandon and Kasturi, 1975</xref>; <xref ref-type="bibr" rid="bibr118-1753944713477518">Tryka <italic>et al</italic>. 1985</xref>]. In contrast, the main changes found in patients with systolic heart failure were discrete medial hypertrophy of the distal arterioles (&lt;600 µm) and only mild or no vascular intimal fibrosis was detected [<xref ref-type="bibr" rid="bibr29-1753944713477518">Delgado <italic>et al</italic>. 2005</xref>]. Vasodilator testing of systolic heart failure patients supports these findings as at least a partially preserved vascular responsiveness of the pulmonary arterioles was demonstrated [<xref ref-type="bibr" rid="bibr15-1753944713477518">Braun <italic>et al</italic>. 2007</xref>].</p>
<p>In our own experience of over 400 cases of provocative vasodilator testing (Iloprost ± sildenafil), a nonexistence of pulmonary vasoreactivity or ‘fixed’ PH could be found in &lt;10% of patients with PH due to systolic heart failure. In these nonresponsive cases, irreversible obstructive remodelling was suspected. The International Society for Heart and Lung Transplantation (ISHLT) has defined unresponsive ‘fixed’ PH in patients with systolic heart failure awaiting heart transplantation as when the systolic PAP remains &gt;50 mmHg, the pulmonary vascular resistance (PVR) &gt;5 WU (Wood Units) and the TPG &gt;16 mmHg after pharmacological testing [<xref ref-type="bibr" rid="bibr91-1753944713477518">Mehra <italic>et al</italic>. 2006</xref>]. However, even this condition may be reversible, as effective unloading of the left heart by left ventricular (LV) assist devices has been shown to induce significant regressions of these functional and structural precapillary remodelling processes, allowing a lower risk heart transplantation at a later time point [<xref ref-type="bibr" rid="bibr89-1753944713477518">Martin <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr124-1753944713477518">Zimpfer <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section5-1753944713477518">
<title>Haemodynamic definitions of reactive <italic>versus</italic> passive PH due to left heart disease (LHD)</title>
<sec id="section6-1753944713477518">
<title>Transpulmonary gradient</title>
<p>For the first time, the European Society of Cardiology (ESC) <italic>Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension</italic> differentiates between passive and reactive PH due to left heart disease according to very specific transpulmonary gradient (TPG) cutoff values. The authors selected a TPG limit of &gt;12 mmHg as reactive PH and ≤12 mmHg as passive PH [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>] (<xref ref-type="fig" rid="fig3-1753944713477518">Figure 3</xref>).</p>
<fig id="fig3-1753944713477518" position="float">
<label>Figure 3.</label>
<caption>
<p>Differentiation in passive <italic>versus</italic> reactive ‘out of proportion’ pulmonary hypertension according to ESC guidelines [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>].</p>
<p>ESC: European Society of Cardiology; LAP: left atrial pressure; PAP: pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; PH: pulmonary hypertension; TPG: transpulmonary gradient (PAPmean – PCWPmean).</p>
</caption>
<graphic xlink:href="10.1177_1753944713477518-fig3.tif"/>
</fig>
<p>However, this arbitrarily selected cutoff lacks prospectively designed studies for precise pathophysiological, clinical and prognostic discrimination. In addition, the reactive PH was also referred to as ‘out of proportion’ PH by the same authors [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al.</italic> 2009</xref>], which means that every elevation of PAmean with a TPG &gt;12 mmHg is considered ‘out of proportion’ to the underlying cause of left heart disease. Such nomenclature completely ignores the very complex function of the pulmonary vascular bed to regulate the interplay between the often very differently affected right and left ventricular function. A dynamically changing TPG/PVR could regulate the afterload sensitive ejection of the right ventricle in order to adjust the ventricular preload of a diseased left heart and to protect it from a volume overload. In addition, defining a TPG cutoff contradicts the physiology of the pulmonary vascular bed. The gradient between PAmean and PCWP is sensitive to changes in cardiac output and both the recruitment and distension of the pulmonary vessels, which decrease the upstream transmission of left atrial pressure. Furthermore, pulmonary blood flow is pulsatile, with systolic and mean PAP and, logically, also the TPG determined by stroke volume and arterial compliance [<xref ref-type="bibr" rid="bibr96-1753944713477518">Naeije <italic>et al</italic>. 2012</xref>].</p>
</sec>
<sec id="section7-1753944713477518">
<title>Diastolic pressure gradient</title>
<p>This discussion shows that, in practice, the TPG may overdiagnose or underdiagnose pulmonary vascular disease in left heart failure. Naeije and colleagues supposed in their very smart review that this could be avoided to a large extent by the use of the gradient between diastolic PAP and PCWP, or ‘diastolic pressure gradient’ (DPG) [<xref ref-type="bibr" rid="bibr96-1753944713477518">Naeije <italic>et al</italic>. 2012</xref>]. The theory behind this is that pulmonary flow reaches a maximum during systole and is inappreciable at the end of diastole. Accordingly, diastolic PAP in a normal pulmonary circulation is approximately equal to the pressure in left atrium (LA), more specifically, the mean pressure during the atrial systole (or ventricular diastolic phase). In a small haemodynamic study in healthy volunteers, an upper limit of 5 mmHg was established for the normal DPG [<xref ref-type="bibr" rid="bibr61-1753944713477518">Harvey <italic>et al</italic>. 1971</xref>]. Values above 5 mmHg in combination with signs of elevated left atrial pressure would indicate an ‘out of proportion’ PH in patients with PH due to left heart disease.</p>
<p>The advantage of using DPG instead of TPG lies in the reduced sensitivity to changes in the cardiac output, stroke volume and absolute values of atrial pressure [<xref ref-type="bibr" rid="bibr96-1753944713477518">Naeije <italic>et al</italic>. 2012</xref>]. However, these are hypotheses, and new pharmacological and haemodynamic clinical studies are needed to clarify these considerations.</p>
</sec>
<sec id="section8-1753944713477518">
<title>Pulmonary vascular resistance</title>
<p>Recently, different authors proposed that a PVR &gt;3 WU <italic>versus</italic> ≤3 WU could differentiate between reactive and passive PH [<xref ref-type="bibr" rid="bibr4-1753944713477518">Aronson <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr71-1753944713477518">Khush <italic>et al</italic>. 2009</xref>]. However, PVR is influenced by two variables: TPG and cardiac output. In particular, the determination of the right cardiac output by thermodilution or by the Fick method is often incorrect and unreliable. An example of this is that a combination of a highly normal TPG of 10 mmHg and a very low cardiac output (CO) of 3 l/min would also result in a PVR (PVR = TPG/CO) &gt;3 WU, which does not really indicate an ‘out of proportion’ PH.</p>
</sec>
</sec>
<sec id="section9-1753944713477518">
<title>Determinants of PH in left heart disease</title>
<sec id="section10-1753944713477518">
<title>PH due to left ventricular systolic or diastolic dysfunction</title>
<p>The hallmark of PH in left heart disease is elevated left atrial (LA) and pulmonary venous pressure. Elevated LA pressure in patients with left ventricular dysfunction is predominantly the result of backward transmitted elevated left ventricular filling pressure (LVEDP) [<xref ref-type="bibr" rid="bibr34-1753944713477518">Enriquez-Sarano <italic>et al</italic>. 1997</xref>; <xref ref-type="bibr" rid="bibr70-1753944713477518">Kerem <italic>et al</italic>. 2010</xref>]. Increased LV filling pressure is associated with dysfunctional early diastolic relaxation and late filling compliance in patients with primary diastolic heart failure (heart failure with preserved ejection fraction, HFPEF). In systolic heart failure patients (HF with reduced EF, HFREF), heightened filling pressure is the mixed consequence of a right shift of the Frank Starling curve to a higher LVEDP and, in most cases, to an additional diastolic dysfunction. Owing to the open mitral valve, an elevated left ventricular filling pressure determines the LA pressure with an equalizing of pressure during the late ventricular diastole (communicating holes). The left atrium is filled (atrial diastole) by the pulmonary venous blood during the left ventricular systole. The resulting left atrial filling pressure (v-wave), in turn, is determined mainly by the compliance of the left atrium. That means that the diastolic LA pressure, as a direct reflection of the LVEDP, is added by the atrial filling pressure (v-wave) during the cardiac cycle (for example in <xref ref-type="fig" rid="fig5-1753944713477518">Figure 5</xref> below). The impact of LA stiffness for the generation of the v-wave is supported by the data of Kurt and colleagues [<xref ref-type="bibr" rid="bibr75-1753944713477518">Kurt <italic>et al</italic>. 2009</xref>]. They showed that the LA stiffness is tightly related to the elevated pulmonary pressure in patients with both HFREF and HFPEF.</p>
<p>In addition, some patients have increased LA pressure due to atrial and ventricular interdependence mediated by a constrained pericardial sack relative to an enlarged right atrium and/or right ventricle.</p>
<p>Different grades of accompanying mitral regurgitations have been described, especially in patients with systolic heart failure, and also in patients with HFPEF [<xref ref-type="bibr" rid="bibr88-1753944713477518">Marechaux <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr107-1753944713477518">Rossi <italic>et al</italic>. 2011</xref>]. In such cases, the systolic regurgitation fraction of the diseased mitral valve is added to the systolic LA filling volume. Depending on the LA stiffness, this results in further increases of the left atrial filling pressure (v-wave) and the consecutive pulmonary pressure.</p>
</sec>
<sec id="section11-1753944713477518">
<title>PH due to valvular disease</title>
<p>Mitral valve regurgitation increases the v-wave of the LA pressure curve very directly depending on the regurgitation volume, LA compliance and LVEDP [<xref ref-type="bibr" rid="bibr9-1753944713477518">Barbieri <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr110-1753944713477518">Saraiva <italic>et al</italic>. 2009</xref>].</p>
<p>In turn, mitral valve stenosis obstructs the diastolic emptying of the LA. Elevated LA pressure (a-wave) during the diastole can be observed. The additional systolic filling results in an elevated systolic pressure (v-wave) because of the end-diastolic volume overload of the LA [<xref ref-type="bibr" rid="bibr118-1753944713477518">Tryka <italic>et al</italic>. 1985</xref>].</p>
<p>In contrast to the direct effects of mitral valve disease on pulmonary pressure elevation, the development of pulmonary hypertension in aortic valve disorders is predominantly not mediated by the diseased valve itself. Over time, aortic valve stenosis as well as aortic valve insufficiency leads to progressive left ventricular systolic and diastolic dysfunction, reflected by LVEDP. The latter and often accompanying mitral valve insufficiencies are the main causes of PH in aortic valve disease [<xref ref-type="bibr" rid="bibr68-1753944713477518">Kapoor <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr87-1753944713477518">Malouf <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr120-1753944713477518">Varadarajan and Pai, 2012</xref>].</p>
<p>In conclusion, the development of PH due to systolic/diastolic myocardial dysfunction and/or valvular disease is dependent on an elevated left ventricular filling pressure, mitral valve disease, impaired compliance of the left atrium, and a variable precapillary transpulmonary pressure gradient (<xref ref-type="fig" rid="fig4-1753944713477518">Figure 4</xref>).</p>
<fig id="fig4-1753944713477518" position="float">
<label>Figure 4.</label>
<caption>
<p>Proposed mechanisms for the development of pulmonary hypertension in valvular heart disease.</p>
<p>DF: dysfunction; FMI: functional mitral valve insufficiency; LA: left atrium; LV: left ventricle; LVEDP: left ventricular end diastolic pressure; MI: mitral valve insufficiency; MS: mitral stenosis; PH: pulmonary hypertension.</p>
</caption>
<graphic xlink:href="10.1177_1753944713477518-fig4.tif"/>
</fig>
</sec>
</sec>
<sec id="section12-1753944713477518">
<title>Epidemiology and prognosis of PH in left heart disease</title>
<p>PH owing to left heart disease is a common phenomenon that appears to be highly relevant for the patient’s outcome [<xref ref-type="bibr" rid="bibr9-1753944713477518">Barbieri <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr18-1753944713477518">Bursi <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr26-1753944713477518">Damy <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr87-1753944713477518">Malouf <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr114-1753944713477518">Szwejkowski <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr120-1753944713477518">Varadarajan and Pai, 2012</xref>]. However, the development, severity and prognostic relevance are variable and are dependent on the pathophysiology of the different underlying left heart diseases (<xref ref-type="table" rid="table1-1753944713477518">Table 1</xref>).</p>
<table-wrap id="table1-1753944713477518" position="float">
<label>Table 1.</label>
<caption>
<p>Classification of PH due to left heart disease.</p>
</caption>
<graphic alternate-form-of="table1-1753944713477518" xlink:href="10.1177_1753944713477518-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
</colgroup>
<tbody>
<tr>
<td><bold>• Heart failure with preserved EF (HFPEF)</bold></td>
</tr>
<tr>
<td> –Hypertensive heart disease</td>
</tr>
<tr>
<td> –Diabetic CMP</td>
</tr>
<tr>
<td> –Hypertrophic (-obstructive) CMP</td>
</tr>
<tr>
<td> –Restrictive/infiltrative CMP</td>
</tr>
<tr>
<td> –Ischemic diastolic dysfunction</td>
</tr>
<tr>
<td><bold>• Heart failure with reduced EF (HFREF)</bold></td>
</tr>
<tr>
<td> –Ischemic CMP</td>
</tr>
<tr>
<td> –Dilatative CMP</td>
</tr>
<tr>
<td><bold>• Valvular heart disease</bold></td>
</tr>
<tr>
<td> –Mitral valve stenosis/insufficiency</td>
</tr>
<tr>
<td> –Aortic valve stenosis/insuffciency</td>
</tr>
<tr>
<td><bold>• Others</bold></td>
</tr>
<tr>
<td> –Constrictive pericarditis</td>
</tr>
<tr>
<td> –Tri-atrial heart</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1753944713477518">
<p>CMP: cardiomyopathy</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section13-1753944713477518">
<title>Heart failure with preserved ejection fraction (HFPEF)</title>
<p>The prevalence of diastolic heart failure (HFPEF) is in up to 25% of the predominantly elderly population [<xref ref-type="bibr" rid="bibr76-1753944713477518">Kuznetsova <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr117-1753944713477518">Tribouilloy <italic>et al</italic>. 2008</xref>]. Most HFPEF patients have elevated pulmonary arterial pressure because of an increased left ventricular filling pressure. Recent data from Olmsted County, Minnesota, USA, confirm that 83% of patients with HFPEF (<italic>n</italic> = 224) develop pulmonary hypertension [pulmonary artery systolic pressure (PASP) &gt;35 mmHg]. In comparison, only 8% of patients with sole arterial hypertension were detected to have PH [<xref ref-type="bibr" rid="bibr78-1753944713477518">Lam <italic>et al</italic>. 2009b</xref>]. PASP elevation was highly predictive for survival in HFPEF.</p>
<p>Although the increased left ventricular filling pressure (PCWP, LVEDP) contributes to PH, it does not fully explain the severity of PH in HFPEF, suggesting that a component of precapilliary pulmonary pressure elevation (TPG) also contributes. However, the PCWP values were estimated only by echocardiography in which the ratio of early transmitral flow velocity (E) to early mitral annular diastolic velocity (e′, tissue doppler) was used. Up to now, this method is not likely to replace the right heart catheter, especially to determine the resulting transpulmonary gradient precisely [<xref ref-type="bibr" rid="bibr11-1753944713477518">Bhella <italic>et al</italic>. 2011</xref>]. Haemodynamic studies are necessary to recognize the true extent of the precapilliary component of PH in HFPEF.</p>
</sec>
<sec id="section14-1753944713477518">
<title>Heart failure with reduced EF (HFREF)</title>
<p>Epidemiological data and observational studies have shown that at least two-thirds of patients with severe systolic heart failure develop PH [<xref ref-type="bibr" rid="bibr20-1753944713477518">Cappola <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr43-1753944713477518">Ghio <italic>et al</italic>. 2001</xref>]. PH in HFREF is associated with an increased mortality, hospitalization rate and need for cardiac transplantation [<xref ref-type="bibr" rid="bibr1-1753944713477518">Abramson <italic>et al</italic>. 1992</xref>; <xref ref-type="bibr" rid="bibr20-1753944713477518">Cappola <italic>et al</italic>. 2002</xref>]. Mean systemic pressure and mean pulmonary artery pressure in patients with newly diagnosed cardiomyopathy (<italic>n</italic> = 1134) have emerged as important haemodynamic predictors of death [<xref ref-type="bibr" rid="bibr20-1753944713477518">Cappola <italic>et al</italic>. 2002</xref>]. As in the case of PAH, chronic elevation of PASP results in permanent right ventricular afterload stress, which may ultimately lead to progressive right heart failure [<xref ref-type="bibr" rid="bibr28-1753944713477518">de Groote <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr57-1753944713477518">Haddad <italic>et al</italic>. 2008a</xref>, <xref ref-type="bibr" rid="bibr58-1753944713477518">2008b</xref>]. Ghio and colleagues [<xref ref-type="bibr" rid="bibr43-1753944713477518">Ghio <italic>et al</italic>. 2001</xref>] demonstrated that the presence of right heart dysfunction in patients with HFREF was associated with a twofold higher mortality than in isolated LV failure.</p>
</sec>
<sec id="section15-1753944713477518">
<title>Passive versus ‘out of proportion’ PH</title>
<p>To the best of the authors’ knowledge, no randomized prospective studies have been published targeting the prognostic value of passive <italic>versus</italic> reactive PH in patients with PH due to left heart disease. Two retrospective analyses carried out in patients with recently decompensated systolic heart failure examined the prognostic implications of PH subtypes. The subtype definitions of PH were based on a PVR cutoff of &gt;3 WU (reactive PH) <italic>versus</italic> ≤3 WU (passive PH) [<xref ref-type="bibr" rid="bibr4-1753944713477518">Aronson <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr71-1753944713477518">Khush <italic>et al</italic>. 2009</xref>]. While Khush and colleagues [<xref ref-type="bibr" rid="bibr71-1753944713477518">Khush <italic>et al</italic>. 2009</xref>] found that the PVR-based PH subtypes of the ESCAPE (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) trial were not associated with a different six-month survival, analysis of the VMAC (Vasodilation in the Management of Acute Congestive Heart Failure) trial data showed a twofold higher six-month mortality in patients with a PVR &gt;3 WU [<xref ref-type="bibr" rid="bibr4-1753944713477518">Aronson <italic>et al</italic>. 2011</xref>].</p>
<p>To interpret these partly conflicting results, we have to remember that PVR is a calculated parameter, namely the quotient of TPG and cardiac output. Therefore, a high PVR may result from an elevated TPG and/or a lowered cardiac output. Hence, a normal TPG (e.g. 9 mmHg) in combination with a very low cardiac output (e.g. 3.0 l/min) would also result in a high PVR of 3 WU, reflecting the compromised LV function but not the intrinsic abnormalities of the pulmonary vascular tree. Indeed, reactive PH patients within the VMAC trial were characterized by significantly higher left ventricular filling pressures and lower stroke volumes than passive PH patients. This implicates their worse LV function in comparison with the passive PH group, which has certainly influenced the worse prognosis too [<xref ref-type="bibr" rid="bibr4-1753944713477518">Aronson <italic>et al</italic>. 2011</xref>].</p>
</sec>
</sec>
<sec id="section16-1753944713477518">
<title>PH in left-sided valvular disease</title>
<p>The prevalence of PH in left-sided valvular disease correlates with the severity of the valve disease, the concomitant diastolic dysfunction of the left atrium and ventricle, and clinical symptoms [<xref ref-type="bibr" rid="bibr14-1753944713477518">Bonow <italic>et al</italic>. 2006</xref>, <xref ref-type="bibr" rid="bibr13-1753944713477518">2008</xref>].</p>
<p>Mitral stenosis is the classical disease associated with PH in left heart disease. The prevalence of PH varies depending on the severity of the valvular disease and may be as common as 75% [<xref ref-type="bibr" rid="bibr14-1753944713477518">Bonow <italic>et al</italic>. 2006</xref>; <xref ref-type="bibr" rid="bibr60-1753944713477518">Hart <italic>et al</italic>. 2010</xref>]. In contrast, mild, moderate or moderate-to-severe mitral valve regurgitation is associated with PH pressure &gt;40 mmHg in only 14%, 26% and 44% of affected patients, respectively [<xref ref-type="bibr" rid="bibr101-1753944713477518">Parker <italic>et al</italic>. 2010</xref>]. However, it was shown recently that exercise-induced PH [systolic pulmonary arterial pressure (PAP) &gt;60 mmHg] was common in patients with asymptomatic moderate mitral regurgitation ith a prevalence of more than 46% (compared with 15% of PH at rest) [<xref ref-type="bibr" rid="bibr86-1753944713477518">Magne <italic>et al</italic>. 2010</xref>]. Notably, the severity of mitral regurgitation did not correlate with the systolic PAP. In the study by Saraiva and colleagues [<xref ref-type="bibr" rid="bibr110-1753944713477518">Saraiva <italic>et al</italic>. 2009</xref>], the only independent echocardiographic predictor of PH was the E/A ratio reflecting the LV diastolic dysfunction. This suggests that LA volume overload may be balanced by LA compliance and/or pulmonary vascular capacitance and resistance even when chronic mitral regurgitation is severe.</p>
<p>Compared with mitral stenosis, the prevalence of PH in patients with aortic stenosis is lower (approximately 30%) [<xref ref-type="bibr" rid="bibr36-1753944713477518">Faggiano <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr66-1753944713477518">Johnson <italic>et al</italic>. 1988</xref>; <xref ref-type="bibr" rid="bibr87-1753944713477518">Malouf <italic>et al</italic>. 2002</xref>]. Although the risk of perioperative and postoperative heart failure and mortality is increased in these patients, only aortic valve replacement may improve the extremely limited prognosis [<xref ref-type="bibr" rid="bibr87-1753944713477518">Malouf <italic>et al</italic>. 2002</xref>; <xref ref-type="bibr" rid="bibr125-1753944713477518">Zuern <italic>et al</italic>. 2012</xref>]. In patients with mild, moderate and severe aortic regurgitation, a PH with a pulmonary systolic pressure &gt;40 mmHg was found in 26%, 28% and 18%, respectively [<xref ref-type="bibr" rid="bibr101-1753944713477518">Parker <italic>et al</italic>. 2010</xref>].</p>
<p>Even though PH constitutes a risk factor for valvular surgery, the surgical correction of significant valvular disease results in a considerable reduction of PH in most cases [<xref ref-type="bibr" rid="bibr119-1753944713477518">Vahanian <italic>et al</italic>. 2007</xref>].</p>
</sec>
<sec id="section17-1753944713477518">
<title>Right ventricular function and PH due to left heart disease</title>
<p>The normal right ventricle (RV) delivers the same stroke volume as the left ventricle, but with one-fifth of its mass and wall thickness, and only 20% of the intrinsic contractility of the left heart [<xref ref-type="bibr" rid="bibr57-1753944713477518">Haddad <italic>et al</italic>. 2008a</xref>, <xref ref-type="bibr" rid="bibr58-1753944713477518">2008b</xref>]. In addition, due to complex crescent-like geometry and myocyte arrangement, the right ventricle is very well-suited to accommodate an increase in volume load, but is extremely afterload sensitive [<xref ref-type="bibr" rid="bibr3-1753944713477518">Anderson <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr58-1753944713477518">Haddad <italic>et al</italic>. 2008b</xref>; <xref ref-type="bibr" rid="bibr100-1753944713477518">Nielsen <italic>et al</italic>. 2009</xref>]. The main adaptive mechanism that enables the right ventricle to maintain an adequate cardiac output is the development of hypertrophy, which can reach an extensive degree especially in the case of chronic mitral valve stenosis. Although this pattern of RV remodelling is often tolerated for many years, it may progress to chamber dilatation, functional tricuspid regurgitation and frank RV failure [<xref ref-type="bibr" rid="bibr21-1753944713477518">Champion <italic>et al</italic>. 2009</xref>]. Wall dilatation especially in combination with increased RV pressure leads to an increased wall stress, which may enhance myocardial oxygen demand, thus provoking ischemia and further RV dysfunction.</p>
<p>In the case of PH due to left heart disease, more different and often combined reasons than only afterload mismatch are responsible for the development of right-sided ventricular dysfunction. Mainly, chronic reductions of the intrinsic contractility of the right ventricular muscle by the same cardiomyopathic process involving the left ventricle, such as myocardial infarction with RV participation, biventricular dilative cardiomyopathy, and biventricular arrhytmogenic right ventricular dysplasia (ARVD), often accompanied by functional tricuspid regurgitation and ventricular interactions, can aggravate the RV dysfunction in comparison to a singular RV afterload increase. Biventricular distributed infiltrative and/or hypertrophic cardiomyopathies can lead to pronounced diastolic LV and RV dysfunction and failure. In addition, Tedford and colleagues [<xref ref-type="bibr" rid="bibr116-1753944713477518">Tedford <italic>et al</italic>. 2012</xref>] recently explained that afterload mismatch in PH due to left heart disease is not the same as in precapilliary pulmonary artery hypertension. They found that the compliance of the pulmonary vascular bed in group II PH is lower at any given PVR in comparison with pulmonary artery hypertension. Higher PCWP appears to enhance net right ventricular afterload by elevating pulsatile load and this may contribute to the further decline of right ventricular function.</p>
<p>The occurrence of right ventricular dysfunction and frank RV failure are undesirable in group II PH, because of the further compromised ventricular forward output and the facilitation of oedema formation by increasing the right ventricular and consecutive atrial pressure [<xref ref-type="bibr" rid="bibr47-1753944713477518">Guazzi and Arena, 2010</xref>; <xref ref-type="bibr" rid="bibr49-1753944713477518">Guazzi and Borlaug, 2012</xref>]. This in itself carries additional multiorgan toxicity, such as interstitial fluid accumulation in the lungs and pleura spaces by compromised lymphatic drainage, hepatic and splanchnic congestion with impaired gut absorption, development of ascites and translocation of gut microbes, and consecutive release of endotoxins with subsequent inflammatory states in heart failure [<xref ref-type="bibr" rid="bibr49-1753944713477518">Guazzi and Borlaug, 2012</xref>; <xref ref-type="bibr" rid="bibr99-1753944713477518">Niebauer <italic>et al</italic>. 1999</xref>]. In summary, progressive RV failure in group II PH aggravates the left heart disease by triggering different pathophysiological mechanisms that worsen not only the clinical symptoms, but also the prognosis of these patients.</p>
<p>Different observational studies have shown that right ventricular dysfunction and failure in patients with PH due to systolic left heart failure is an important predictor for a worse prognosis [<xref ref-type="bibr" rid="bibr28-1753944713477518">de Groote <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr43-1753944713477518">Ghio <italic>et al</italic>. 2001</xref>]. In addition, retrospective analysis of data from BEST (Beta-Blocker Evaluation in Survival <italic>Trial</italic>) highlighted that an impaired right ventricular ejection fraction (RVEF) is associated with lower survival in patients with HFREF. An RVEF especially of &lt;20% was an independent predictor of mortality and hospitalization for HFREF patients [<xref ref-type="bibr" rid="bibr92-1753944713477518">Meyer <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section18-1753944713477518">
<title>Diagnosis</title>
<p>The diagnostic approach of PH due to left heart disease basically corresponds to PAH. It always has the following three goals:</p>
<list id="list1-1753944713477518" list-type="order">
<list-item><p>to objectify the presence of PH;</p></list-item>
<list-item><p>to differentiate between precapilliary (group I, III, IV, V) or postcapilliary (group II) PH;</p></list-item>
<list-item><p>in the case of precapilliary PH, to identify group I or IV diseases in which specific pharmacological or operative therapies, respectively, are indicated and may improve the mostly worse prognosis [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie et al. 2009</xref>].</p></list-item>
</list>
<p>The initial diagnostic workup includes a careful physical examination, chest radiography, electrocardiography and doppler echocardiography. A right heart catheterization is essential to differentiate between PH due to left heart disease (postcapilliary) and precapilliary PH, to measure pulmonary haemodynamics of valvular heart disease, or to evaluate haemodynamics prior to heart transplantation [<xref ref-type="bibr" rid="bibr105-1753944713477518">Rosenkranz et al. 2011a</xref>, <xref ref-type="bibr" rid="bibr106-1753944713477518">Rosenkranz et al. 2011b</xref>].</p>
<p>Common symptoms of patients with PH due to left heart disease are orthopnea, paroxysmal nocturnal dyspnea and exertional dyspnea [<xref ref-type="bibr" rid="bibr47-1753944713477518">Guazzi and Arena, 2010</xref>; <xref ref-type="bibr" rid="bibr49-1753944713477518">Guazzi and Borlaug, 2012</xref>]. Patients with left heart failure display a number of ventilatory abnormalities that are probably related to pulmonary vasculature. In patients with left heart failure, an impaired exercise ventilator efficiency ratio of ventilation to carbon dioxide uptake (VE/Vco<sub>2</sub>) slope is observed, which is related to pulmonary vasoconstriction, RV dysfunction [<xref ref-type="bibr" rid="bibr31-1753944713477518">Di Salvo <italic>et al</italic>. 1995</xref>; <xref ref-type="bibr" rid="bibr103-1753944713477518">Reindl <italic>et al</italic>. 1998</xref>] and adverse clinical events [<xref ref-type="bibr" rid="bibr73-1753944713477518">Kleber <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr82-1753944713477518">Lewis <italic>et al</italic>. 2008</xref>]. The incidence of sleep apnoea as well as oscillatory ventilator patterns during exercise are related to impaired pulmonary vascular haemodynamics, heart minute volume and increased left ventricular filling pressure [<xref ref-type="bibr" rid="bibr51-1753944713477518">Guazzi <italic>et al</italic>. 2005</xref>, <xref ref-type="bibr" rid="bibr48-1753944713477518">2012a</xref>, <xref ref-type="bibr" rid="bibr55-1753944713477518">2012b</xref>; <xref ref-type="bibr" rid="bibr113-1753944713477518">Solin <italic>et al</italic>. 1999</xref>]. Chest radiography may show pulmonary vascular congestion, pleural effusion or pulmonary oedema, and will often reveal cardiomegaly in the case of systolic heart failure. Electrocardiographic signs favouring group II PH include mostly LV hypertrophy, left atrial enlargement or atrial fibrillation [<xref ref-type="bibr" rid="bibr49-1753944713477518">Guazzi and Borlaug, 2012</xref>]. Clinical signs of right heart failure are variable and are more common in advanced stages of biventricular heart failure. In addition, they involve a clinical exercise limitation, fatigue and evidence of specific venous congestion and secondary fluid retention (e.g. peripheral oedema, anasarca or ascites).</p>
<sec id="section19-1753944713477518">
<title>Echocardiography</title>
<p>Echocardiography plays a key role in the initial diagnosis of PH. Typically, transthoracic echocardiography is the primary modality chosen because it provides detailed anatomical and functional information about both ventricles, cardiac valves, pulmonary artery pressure, inferior vena cave width and pericardium [<xref ref-type="bibr" rid="bibr64-1753944713477518">Howlett <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr85-1753944713477518">Lindqvist <italic>et al</italic>. 2008</xref>]. With the use of transoesophageal echo, a more objective assessment of the severity of mitral and aortic regurgitation can be reached.</p>
<p>The PASP can be estimated from the peak tricuspid regurgitation (TR) jet velocity, using the simplified Bernoulli equation and combining this value with an estimate of the right atrial (RA) pressure: PASP = 4(V<sup>2</sup>) + RA pressure, where V is the peak velocity (metres per second) of the TR jet, and RA pressure is estimated from the inferior vena cava diameter and its respiratory changes [<xref ref-type="bibr" rid="bibr109-1753944713477518">Rudski <italic>et al</italic>. 2010</xref>]. Normal resting values are usually defined as a peak TR gradient of ≤2.8 to 2.9 m/s or a peak systolic pressure of 35–36 mmHg, assuming a RA pressure of 3–5 mmHg [<xref ref-type="bibr" rid="bibr8-1753944713477518">Badesch <italic>et al</italic>. 2009</xref>]. This value may increase with age and increasing body surface area [<xref ref-type="bibr" rid="bibr77-1753944713477518">Lam <italic>et al</italic>. 2009a</xref>; <xref ref-type="bibr" rid="bibr90-1753944713477518">McQuillan <italic>et al</italic>. 2001</xref>]. Determination of PASP by the sum of peak RV–RA gradient and RA pressure has been established and proven by multiple studies, but more recent reports have questioned the accuracy of this relationship, particularly at higher PAP [<xref ref-type="bibr" rid="bibr39-1753944713477518">Fisher <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr123-1753944713477518">Yock and Popp, 1984</xref>]. Sources of additional errors include overestimation of RA pressure and the reliance of inadequate Doppler signals. Despite the high usefulness of PASP estimation in clinical praxis, echocardiography is not able to locate with certainty the origin of pulmonary pressure elevation, namely precapillary or postcapilliary, or to differentiate group II PH in reactive or passive PH. At least, in the context of different clinical and echocardiographic signs, some prediction can be reached for distinguishing PAH from PH due to left heart disease [<xref ref-type="bibr" rid="bibr109-1753944713477518">Rudski <italic>et al</italic>. 2010</xref>].</p>
</sec>
<sec id="section20-1753944713477518">
<title>Echocardiography in PH due to heart failure with reduced EF (PH-HFREF)</title>
<p>PH in combination with reduced ejection fraction in dilated left ventricles, including different grades of functional mitral regurgitation, are typical signs of a correct diagnosis. Notably, in patients with concomitant right heart failure and severe tricuspid regurgitation, the Doppler envelope may be cut off because of an early equalization of RV and RA pressure, and the simplified Bernoulli equation may underestimate the RV–RA gradient and the pulmonary resistance [<xref ref-type="bibr" rid="bibr109-1753944713477518">Rudski <italic>et al</italic>. 2010</xref>]</p>
</sec>
<sec id="section21-1753944713477518">
<title>Echocardiogaphy in PH due to heart failure with preserved EF (PH-HFPEF)</title>
<p>Patient demographics provide perhaps the greatest predictive value for the differentiation of PH-HFPEF from PAH. Key risk factors for HFPEF or comorbidities are metabolic syndrome including systemic hypertension, obesity, diabetes mellitus, atrial fibrillation, older age and chronic obstructive lung disease [<xref ref-type="bibr" rid="bibr7-1753944713477518">Aurigemma and Gaasch, 2004</xref>; <xref ref-type="bibr" rid="bibr62-1753944713477518">Ho <italic>et al</italic>. 2012</xref>]. Echocardiographic findings suggestive of PH-HFPEF include the combination of preserved ejection function with left atrial dilatation, left ventricular hypertrophy, abnormal Doppler estimates of mitral and pulmonary venous flow velocity, and mitral tissue Doppler velocities. The ratio of early transmittal flow velocity (E) to tissue Doppler early diastolic (e′) mitral annular velocity (E/e′ ratio) has been widely accepted as a noninvasive measure of left ventricular filling pressure [<xref ref-type="bibr" rid="bibr5-1753944713477518">Arques <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr32-1753944713477518">Dokainish <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr98-1753944713477518">Nagueh <italic>et al</italic>. 1997</xref>]. However, a number of recent studies have questioned the value of this tool to determine the degree of left ventricular diastolic dysfunction and to unambiguously distinguish between PAH and PH due to left heart disease [<xref ref-type="bibr" rid="bibr11-1753944713477518">Bhella <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr95-1753944713477518">Mullens <italic>et al</italic>. 2009</xref>].</p>
</sec>
<sec id="section22-1753944713477518">
<title>Right heart catheterization</title>
<p>The European Society of Cardiology and the European Respiratory Society (ERS) guidelines do not provide a clear recommendation regarding the indication for right heart catheterization in patients with suspected group II PH. Indeed, only the careful and precise invasive measurement of the mean pulmonary pressure (≥25 mmHg) and left ventricular filling pressure (PCWP ≤15 mmHg <italic>versus</italic> &gt;15 mmHg) may diagnose PH and is able to differentiate between precapillary and postcapilliary PH. The same applies to the evaluation of passive <italic>versus</italic> reactive PH regarding the height of TPG and/or PVR and/or diastolic pulmonary pressure gradient (see above in the section, ‘Haemodynamic definitions of reactive <italic>versus</italic> passive PH due to LHD’). Therefore, right heart catheterization should be considered in patients in whom a differentiated diagnosis of PH would alter management [e.g. PAH, chronic thromboembolic PH (CTEPH), valvular heart disease] and in patients with systolic left heart failure being evaluated for heart transplantation.</p>
<p>If right heart catheterization is performed, all parameters that are important to fully characterize pulmonary haemodynamics have to be measured, including a detailed oxymetry for the determination of cardiac output and to avoid overlooking shunt defects. <xref ref-type="fig" rid="fig5-1753944713477518">Figure 5</xref> shows a haemodynamic example of a patient with systolic heart failure and PH, in which conflicting results were provided regarding the differentiation between passive <italic>versus</italic> reactive ‘out of proportion’ PH) [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr105-1753944713477518">Rosenkranz <italic>et al</italic>. 2011a</xref>].</p>
<fig id="fig5-1753944713477518" position="float">
<label>Figure 5.</label>
<caption>
<p>Right heart catheter measurement.</p>
<p>The right heart catheter shows a patient with systolic heart failure and moderate functional mitral insufficiency. Regarding the ESC guidelines, the haemodynamic measurement demonstrates severe reactive (TPG = 11 mmHg) pulmonary hypertension due to left heart disease (a). However, regarding the diastolic pressure gradient, a passive pulmonary hypertension has to be suspected (b). Note the high left atrial v-wave resulting from the moderate FMI and low compliance of the LA.</p>
<p>ESC: European Society of Cardiology; FMI: functional mitral valve insufficiency; LA: left atrium; PAP: pulmonary arterial pressure; PCWP: pulmonary capillary wedge pressure; PG: pressure gradient (PAPdiastolic – PCWPmean); TPG: transpulmonary pressure gradient (PAPmean – PCWPmean), diastole.</p>
</caption>
<graphic xlink:href="10.1177_1753944713477518-fig5.tif"/>
</fig>
<p>It has to be realized that using PCWP as a central variable for diagnosis of group II PH could be associated with different problems. The actual pressure measurement of PCWP may be (pseudo)normal as a result of aggressive diuresis potentially leading to misdiagnosis and mistherapy of the PH subtype [<xref ref-type="bibr" rid="bibr59-1753944713477518">Haddad <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr63-1753944713477518">Hoeper <italic>et al</italic>. 2009</xref>]. A volume challenge (e.g. 500–1000 ml normal saline over 5–10 min) or exercise haemodynamics have been proposed to identify or exclude LV dysfunction and consecutive dynamic PH [<xref ref-type="bibr" rid="bibr46-1753944713477518">Grunig <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr74-1753944713477518">Kovacs <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr105-1753944713477518">Rosenkranz <italic>et al</italic>. 2011a</xref>, <xref ref-type="bibr" rid="bibr106-1753944713477518">2011b</xref>].</p>
<p>In heart transplant candidates, the careful determination of the TPG (PAmean – PCWP) and cardiac output are especially important because the persistent increase of the PVR &gt;2.5 WU and/or TPG &gt;15 is associated with an up to threefold rate of postoperative right heart failure and mortality [<xref ref-type="bibr" rid="bibr22-1753944713477518">Chang <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr27-1753944713477518">de Groote <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr91-1753944713477518">Mehra <italic>et al</italic>. 2006</xref>].</p>
</sec>
<sec id="section23-1753944713477518">
<title>Diagnosis of right ventricular dysfunction</title>
<p>Right ventricular systolic dysfunction and failure in patients with PH due to left heart and valvular disease is an important predictor of a worse prognosis, but the analysis of right ventricular systolic function remains a difficult task. As the RV is positioned close to the sternum and is also very complex in its geometric shape and wall motion pattern, assessment by two-dimensional (2D) echocardiography is limited [<xref ref-type="bibr" rid="bibr109-1753944713477518">Rudski <italic>et al</italic>. 2010</xref>]. In addition, there is a paucity of ultrasound studies providing normal reference values of right heart size and function. Radionuclide angiography and magnetic resonance imaging (MRI) are considered as the gold standard for the determination of right ventricle ejection function (RVEF) [<xref ref-type="bibr" rid="bibr28-1753944713477518">de Groote <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr72-1753944713477518">Kind <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr92-1753944713477518">Meyer <italic>et al</italic>. 2010</xref>]. Alternative echocardiographic methods for the estimation of RV systolic function are fractional area change (FAC), myocardial performance index (MPI), tricuspid annular plane systolic excursion (TAPSE), or tissue Doppler peak systolic tricuspid annular velocity (STr) [<xref ref-type="bibr" rid="bibr85-1753944713477518">Lindqvist <italic>et al</italic>. 2008</xref>; <xref ref-type="bibr" rid="bibr109-1753944713477518">Rudski <italic>et al</italic>. 2010</xref>]. These parameters are simple to collect, reproducible and useful for risk stratification, at least for patients with systolic heart failure. Recently, in a retrospective analysis of 527 patients with stable systolic heart failure, best cutoff values for a longer cardiac survival were 37% RVEF (radionuclide angiography), 9.7 cm/s STr and 18.5 mm TAPSE determined by echo [<xref ref-type="bibr" rid="bibr28-1753944713477518">de Groote <italic>et al</italic>. 2012</xref>].</p>
<p>More sophisticated techniques, such as MRI flow measurements, the determination of myocardial acceleration during isovolumetric contraction, regional RV strain and strain rate by echo, or the invasive evaluation of pressure volume loop by conductance catheters, are reserved for specific clinical and research applications in experienced laboratories.</p>
</sec>
</sec>
<sec id="section24-1753944713477518">
<title>Management of PH due to left heart disease</title>
<p>PH is a strong prognostic factor in patients with left heart disease. However, no specific therapy for the treatment of PH due to left heart disease has been established to date. What are the causes of this therapeutic dilemma?</p>
<p>To answer this question, we have to remember the determinants of PH in left heart disease to identify the therapeutic targets:</p>
<list id="list2-1753944713477518" list-type="order">
<list-item><p>Pulmonary venous transmission of elevated left atrial pressure, induced by mitral valve disease and/or increased left ventricular filling pressure as the predominant postcapilliary part</p></list-item>
<list-item><p>The precapilliary generated pulmonary vascular resistance elevation, currently measured as elevated TPG, diastolic PAP gradient or PVR.</p></list-item>
</list>
<p>The management seems clear for the postcapilliary part of PH. In fact, several studies have shown that PH usually regresses after the optimization of heart failure of reduced or preserved ejection function or correction of valvular heart disease [<xref ref-type="bibr" rid="bibr16-1753944713477518">Braunwald <italic>et al</italic>. 1965</xref>; <xref ref-type="bibr" rid="bibr49-1753944713477518">Guazzi and Borlaug, 2012</xref>; <xref ref-type="bibr" rid="bibr80-1753944713477518">Levine <italic>et al</italic>. 1989</xref>; <xref ref-type="bibr" rid="bibr104-1753944713477518">Rosario <italic>et al</italic>. 1998</xref>; <xref ref-type="bibr" rid="bibr124-1753944713477518">Zimpfer <italic>et al</italic>. 2007</xref>]. Application of established heart failure therapies, such as renin angiotensin aldosteron system (RAAS) inhibitors, ß-blockers, ivabradin and diuretics, especially in patients with left heart failure may improve PH through reduction of filling pressure and functional mitral insufficiency [<xref ref-type="bibr" rid="bibr104-1753944713477518">Rosario <italic>et al</italic>. 1998</xref>]. Cardiac resynchronization therapy (CRT) in patients with systolic heart failure and wide QRS complex within the electrocardiogram may improve pulmonary haemodynamics, such as PAP, and PVR and RV remodelling [<xref ref-type="bibr" rid="bibr12-1753944713477518">Bleeker <italic>et al</italic>. 2005</xref>]. However, further studies are required regarding the mechanisms, because these benefits seem to be predominantly mediated by the resynchronization of LV function, including improvements of both systolic and diastolic function [lowering LVEDP and left atrial pressure (LAP)/PCWP] and the reduction of functional mitral insufficiency (lowering LAP/PCWP).</p>
<p>The existence of moderate or severe functional mitral valve insufficiency in patients with advanced systolic heart failure deteriorates the quality of life, exercise capacity and prognosis. The reduction of the concomitant mitral insufficiency by newer interventional techniques, such as mitral clip therapy, has been shown to improve the exercise capacity and quality of life of those patients affected [<xref ref-type="bibr" rid="bibr6-1753944713477518">Auricchio <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr41-1753944713477518">Gaemperli <italic>et al</italic>. 2012</xref>; <xref ref-type="bibr" rid="bibr108-1753944713477518">Rudolph <italic>et al</italic>. 2011</xref>; <xref ref-type="bibr" rid="bibr121-1753944713477518">Whitlow <italic>et al</italic>. 2012</xref>]. The clinical benefits are mainly suspected by lowering the postcapilliary pressure elevation (LAP/PCWP), which results in a decrease of PAP and right ventricular afterload [<xref ref-type="bibr" rid="bibr40-1753944713477518">Franzen <italic>et al</italic>. 2011</xref>].</p>
<p>In summary, optimizing heart failure regimens (and corrective valve surgery in primary valve disease) represents the cornerstone of the treatment of PH due to left heart disease. However, none of these therapeutic options, which may reduce the PH globally, have been systematically evaluated regarding the specific effects on pulmonary vascular tone, compliance, resistance, or structure (<xref ref-type="fig" rid="fig6-1753944713477518">Figure 6</xref>).</p>
<fig id="fig6-1753944713477518" position="float">
<label>Figure 6.</label>
<caption>
<p>Therapeutic management of pulmonary hypertension due to left heart disease (ESC guidelines) [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>].</p>
<p>ESC: European Society of Cardiology; HFPEF: heart failure with preserved ejection function; HFREF: heart failure in patients with reduced ejection fraction; HTX: heart transplantation; LAP: left atrial pressure; PCWP: pulmonary capillary wedge pressure; TPG: transpulmonary pressure.</p>
</caption>
<graphic xlink:href="10.1177_1753944713477518-fig6.tif"/>
</fig>
<p>What are the data about the supposed second therapeutic target: the precapilliary derived pulmonary arterial resistance elevation? It is interesting that therapeutic concepts to modulate, very specifically, the precapilliary pulmonary vascular resistance in PH due to left heart disease have not really been established. Various authors, including the ESC <italic>Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension</italic> have proposed that ‘out of proportion’ PH in these patients could be a therapeutic target [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>; <xref ref-type="bibr" rid="bibr47-1753944713477518">Guazzi and Arena, 2010</xref>; <xref ref-type="bibr" rid="bibr49-1753944713477518">Guazzi and Borlaug, 2012</xref>; <xref ref-type="bibr" rid="bibr106-1753944713477518">Rosenkranz <italic>et al</italic>. 2011b</xref>]. The transpulmonary gradient &gt;12 mmHg has been recommended for the detection of intrinsic pulmonary vascular precapilliary disease and ‘out of proportion’ PH in these patients. As we have pointed out, this value is arbitrary, because the TPG is a highly dynamic parameter. How much pulmonary hypertension secondary to advanced left heart failure results is the passive consequence on an increase in LA pressure can be observed after LV assist system implantations. Several different groups have shown that mechanical LV unloading is able to reverse previously suspected ‘fixed’ precapilliary TPG or PVR, allowing candidacy for heart transplantation [<xref ref-type="bibr" rid="bibr10-1753944713477518">Beyersdorf <italic>et al</italic>. 2010</xref>; <xref ref-type="bibr" rid="bibr35-1753944713477518">Etz <italic>et al</italic>. 2007</xref>; <xref ref-type="bibr" rid="bibr93-1753944713477518">Mikus <italic>et al</italic>. 2011a</xref>, <xref ref-type="bibr" rid="bibr94-1753944713477518">2011b</xref>]. If the proposed DPG is superior to the TPG or PVR for the diagnosis of frank ‘out of proportion’ has yet to be proven [<xref ref-type="bibr" rid="bibr96-1753944713477518">Naeije <italic>et al</italic>. 2012</xref>].</p>
<p>In conclusion, we do not yet really know which degree of precapilliary pressure elevation is ‘out of proportion’ and which is basically protective against volume overload of the diseased left ventricle. In addition, we do not yet have a reliable parameter to differentiate the passive from the ‘out of proportion’ situation.</p>
<p>Are there alternative strategies to this dilemma? We suggest abandoning the unilateral view on the precapilliary pressure gradient in favour of a more interactive and integrated approach between pulmonary vascular blood flow and left atrial/ventricular filling behaviour. In this context two approaches could be envisaged:</p>
<sec id="section25-1753944713477518">
<title>Approach 1: Develop a test procedure</title>
<p>This approach allows a very selective lowering of the elevated precapilliary pressure gradient in a very predictable and gradual manner.</p>
<p>In the case of protective passive PH, the filling pressure would significantly increase because of an inadequate volume overload of the LA and LV. The proposed therapy of such protective passive PH would solely include procedures that unload the LV, such as vasodilators, diuretics or LV assist devices.</p>
<p>In the ‘out of proportion’ situation, gradual lowering of the precapilliary pressure gradient in a (high) normal range should not result in a left ventricular and left atrial volume overload. The filling pressure should increase. A therapy that selectively targets the precapilliary pulmonary vascular disease could be considered in these cases. However, because of co-existing left ventricular dysfunction, a balanced decrease of the pulmonary and systemic resistance would be preferable (<xref ref-type="fig" rid="fig7-1753944713477518">Figure 7</xref>).</p>
<fig id="fig7-1753944713477518" position="float">
<label>Figure 7.</label>
<caption>
<p>Hypothesis for alternative definition of passive protective <italic>versus</italic> ‘out of proportion’ pulmonary hypertension in left ventricular disease (TPG &gt;12 mmHg) and proposed resulting therapy strategies.</p>
<p>CI: cardiac index; DPA-PG: diastolic PA pressure gradient (PAdiastolic - PCWPmean); FMI: functional mitral insufficiency; LA: left atrium; LV: left ventricle; OT of TVD: optimized therapy of left ventricular dysfunction; PCWP: pulmonary capillary wedge pressure; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; SVR: systemic vascular resistance; TPG: transpulmonary pressure.</p>
</caption>
<graphic xlink:href="10.1177_1753944713477518-fig7.tif"/>
</fig>
<p>Additional haemodynamic parameters, such as cardiac index and right ventricular filling pressure, have to be measured and critically evaluated during such a test procedure. It seems to be very useful to analyse not only filling pressure, but also the intrinsic diastolic function of the diseased ventricle, left-side pressure–volume loops (conductance catheter).</p>
<p>Recently, Naeije and colleagues [<xref ref-type="bibr" rid="bibr96-1753944713477518">Naeije <italic>et al</italic>. 2012</xref>] proposed DPG-derived diagnostic algorithms (≤5 mmHg <italic>versus</italic> &gt;5 mmHg) to distinguish between passive upstream transmission of left atrial pressure and increased PVR due to pulmonary vasoconstriction and/or pulmonary vascular structural changes. The goal of this algorithm is solely to identify precapilliary pulmonary vascular disease in different disorders such as heart failure, sepsis, hypervolaemia and hypovolaemia. However, the reaction of the diseased left ventricle on selective pulmonary vasodilatation is not integrated with this approach. From our point of view, not only is the isolated understanding of the pulmonary vascular pathology crucial for the evaluation of new and promising options to manage PH due to left heart disease, but also the development of a concept that integrates the (patho)physiology of the pulmonary vascular bed with the upstream and downstream right and left ventricular function and interaction (<xref ref-type="fig" rid="fig7-1753944713477518">Figure 7</xref>).</p>
</sec>
<sec id="section26-1753944713477518">
<title>Approach 2: Develop and use only therapeutics</title>
<p>The second approach would be to develop and use only therapeutics which lower the pulmonary vascular resistance and simultaneously unload the left ventricle in a very balanced manner.</p>
<p>Above a normal TPG (about 5–9 mmHg), a further differentiation in reactive protective PH or ‘out of proportion’ PH would not be necessary because of the simultaneous decrease of PVR and systemic vascular resistance (SVR). Different medications, originally approved in PAH (group I), with additional vasodilating effects on the systemic circulation have been examined in patients with systolic heart failure during the past few years. However, the results were very disappointing regarding both endothelin antagonists (bosentan, tezosentant, darusentan) and intravenous prostaglandin application (Flolan). In the Flolan International Randomized Survival Trial, the use of low dose epoprostenol was associated with excess mortality, perhaps because of the cyclic adenosine monophosphate (cAMP) dependent positive inotropic effects of the substance [<xref ref-type="bibr" rid="bibr19-1753944713477518">Califf <italic>et al</italic>. 1997</xref>; <xref ref-type="bibr" rid="bibr111-1753944713477518">Shan <italic>et al</italic>. 2012</xref>]. The endothelin receptor blockade in patients with systolic heart failure was associated with only neutral effects at best [<xref ref-type="bibr" rid="bibr2-1753944713477518">Anand <italic>et al</italic>. 2004</xref>; <xref ref-type="bibr" rid="bibr67-1753944713477518">Kalra <italic>et al</italic>. 2002</xref>]. It should be noted, however, that PH was not a mandatory inclusion criteria in all these studies.</p>
<p>The results of a number of pilot trials that examined the effects of a third class of PH-specific drugs, the PDE-5 inhibitors, are more promising. At this time, only sildenafil has been studied in patients with PH due to both systolic and diastolic heart failure. Both acute and chronic trials in patients with PH due to systolic heart failure have shown that sildenafil improves exercise capacity, ventilation efficiency, breathing patterns including exercise oscillatory breathing, and quality of life. These effects may be due to the beneficial effects on pulmonary vascular tone and RV function, reduction in PCWP, and direct modulation of the peripheral skeletal muscle ergoreceptor overstimulation [<xref ref-type="bibr" rid="bibr81-1753944713477518">Lewis <italic>et al</italic>. 2007a</xref>, <xref ref-type="bibr" rid="bibr83-1753944713477518">2007b</xref>]. In addition, sildenafil may improve alveolar-capillary membrane conductance and gas exchange, suggesting an important role for the cyclic guanosine monophosphate (cGMP) downstream pathway in the protection of endothelial permeability [<xref ref-type="bibr" rid="bibr53-1753944713477518">Guazzi <italic>et al</italic>. 2007</xref>, <xref ref-type="bibr" rid="bibr50-1753944713477518">2008</xref>; <xref ref-type="bibr" rid="bibr122-1753944713477518">Yin <italic>et al</italic>. 2011</xref>]. Recently, the effects of a long-term treatment of one year with sildenafil were investigated in a randomized trial of 45 patients with PH and systolic heart failure [<xref ref-type="bibr" rid="bibr54-1753944713477518">Guazzi <italic>et al</italic>. 2004</xref>]. In the sildenafil group, only LV ejection fraction and early diastolic tissue Doppler velocities (E′) significantly increased and a reverse remodelling of the left atrial volume index and LV mass was observed at six months and one year. In another pilot study in patients with PH and HFPEF, long-term therapy with sildenafil resulted in an improvement of LV diastolic function and cardiac index, as well as a marked reduction of RV dilatation and PAP [<xref ref-type="bibr" rid="bibr56-1753944713477518">Guazzi <italic>et al</italic>. 2011</xref>]. Thus, the very promising haemodynamic short- and long-term effects point towards a balanced haemodynamic profile of sildenafil, lowering both the pulmonary and systemic vascular resistance [<xref ref-type="bibr" rid="bibr69-1753944713477518">Katz <italic>et al</italic>. 2000</xref>; <xref ref-type="bibr" rid="bibr79-1753944713477518">Lepore <italic>et al</italic>. 2005</xref>; <xref ref-type="bibr" rid="bibr84-1753944713477518">Lindman <italic>et al</italic>. 2012</xref>].</p>
<p>Despite the encouraging findings, prospective multicentre controlled trials are urgently needed to better define the safety, tolerability and effectiveness of PDE-5 inhibitors in PH due to left ventricular disease. Such studies are especially necessary in the context of the disturbing results of recently published experimental studies. Nagendran and colleagues [<xref ref-type="bibr" rid="bibr97-1753944713477518">Nagendran <italic>et al</italic>. 2007</xref>] and later Shan and colleagues [<xref ref-type="bibr" rid="bibr111-1753944713477518">Shan <italic>et al</italic>. 2012</xref>] found that, in contrast to normal healthy right ventricles, PDE-5 was markedly upregulated in hypertrophied human right heart specimens. Interestingly, PDE-5 inhibition in a rat model of RV hypertrophy and also in human hypertrophied RV specimens resulted in an increase of intrinsic right ventricular inotropy. One explanation could be the suppressed protein kinase G activity in RV hypertrophy, so that the PDE-5 inhibitor induced cGMP increase could lead to inhibition of the cGMP sensitive PDE-3 with an increase of myocardial cAMP levels [<xref ref-type="bibr" rid="bibr97-1753944713477518">Nagendran <italic>et al</italic>. 2007</xref>]. It should be noted, however, that markedly increased PDE-5 immuno-reactivity has also been detected in left ventricular cardiomyocytes of patients with dilated and ischemic cardiomyopathy [<xref ref-type="bibr" rid="bibr102-1753944713477518">Pokreisz <italic>et al</italic>. 2009</xref>]. These findings have important implications because all therapies which lead to increased myocardial cAMP levels, such as PDE-3 inhibitors, epoprostenol and different catecholamines, were associated with excess mortality in patients with systolic heart failure [<xref ref-type="bibr" rid="bibr37-1753944713477518">Felker and O’Connor, 2001a</xref>, <xref ref-type="bibr" rid="bibr38-1753944713477518">2001b</xref>].</p>
<p>In view of these data, European guidelines do not recommend treatments with targeted PAH drugs in patients with left heart failure and PH [<xref ref-type="bibr" rid="bibr42-1753944713477518">Galie <italic>et al</italic>. 2009</xref>]. Instead, the main goal is to establish and maintain a guideline-oriented treatment of the underlying heart failure. Within the specific recommendations of the German Cologne Consensus Conference 2011, it was pointed out that in rare and justified exceptions in which a considerable precapilliary component is the key aspect of the disease and the clinical symptoms, PAH therapy may be considered after the patient has been informed in detail. If patients may be eligible for targeted therapy, the primary objective is the enrolment of patients in ongoing clinical trials. Large expert centres and patient associations (in Germany: pulmonale Hypertonie e.v.) will provide information on this [<xref ref-type="bibr" rid="bibr106-1753944713477518">Rosenkranz <italic>et al</italic>. 2011b</xref>]. The uncritical use of targeted PAH drugs outside of the exceptional cases mentioned above is strongly discouraged.</p>
</sec>
</sec>
<sec id="section27-1753944713477518" sec-type="conclusions">
<title>Conclusion</title>
<p>PH due to left heart disease is the most common cause of PH and, when present, especially with right ventricular dysfunction, is associated with a worse prognosis. The most important determinants of PH due to left heart disease are elevated left ventricular filling pressures, mitral regurgitation and a lowered compliance of the left atrium. In all cases, the resulting elevated left atrial filling pressure causes a passive increase in pulmonary pressure. Passive PH could be superimposed by an active protective and, in some patients, by an ‘out of proportion’ elevated precapilliary pulmonary vasoconstriction and vascular remodelling which lead to a greater or lesser further increase of the PAP and consecutive right ventricular afterload.</p>
<p>Before considering a therapeutic intervention of PH due to left ventricular systolic or diastolic dysfunction, a reliable haemodynamic test or imagine method is needed to differentiate the ‘out of proportion’ PH from the reactive protective form. This seems necessary because the same pulmonary-selective vasodilative therapy would lead to very useful haemodynamic and clinical results in the frank ‘out of proportion’ situation, but possibly to left ventricular volume overload and consecutive pulmonary congestion in the reactive protective form. However, neither the proposed cutoff values of TPG nor PVR are suitable for discriminating between these two PH forms, because both are sensitive to flow, pulmonary vascular recruiting and compliance. Whether the flow insensitive gradient (DPG) between diastolic PAP and PCWP is more suitable for this purpose has to be demonstrated in future clinical investigations. In addition, not only is isolated understanding of its pulmonary vascular pathology crucial for the evaluation of new and promising options to manage PH due to left heart disease, but also the development of a concept that integrates the (patho)physiology of the pulmonary vascular bed with the upstream and downstream right and left ventricular function and interaction.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other">
<label>Authors’ note</label>
<p>Alexander Schmeisser and Hagen Schroetter contributed equally to this paper.</p>
</fn>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest statement</label>
<p>A. Schmeisser: Remunerations for lectures for Actelion, Pfizer, BeyerSchering, and GSK. H. Schroetter: Remunerations for lectures for Lilly, Pfizer. R. Braun-Dulleaus: Remunerations for lectures for Novartis, BeyerSchering.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abramson</surname><given-names>S.</given-names></name>
<name><surname>Burke</surname><given-names>J.</given-names></name>
<name><surname>Kelly</surname><given-names>J.</given-names><suffix>Jr</suffix></name>
<name><surname>Kitchen</surname><given-names>J.</given-names><suffix>III</suffix></name>
<name><surname>Dougherty</surname><given-names>M.</given-names></name>
<name><surname>Yih</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>1992</year>) <article-title>Pulmonary hypertension predicts mortality and morbidity in patients with dilated cardiomyopathy</article-title>. <source>Ann Intern Med</source> <volume>116</volume>: <fpage>888</fpage>–<lpage>895</lpage>.</citation>
</ref>
<ref id="bibr2-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anand</surname><given-names>I.</given-names></name>
<name><surname>McMurray</surname><given-names>J.</given-names></name>
<name><surname>Cohn</surname><given-names>J.</given-names></name>
<name><surname>Konstam</surname><given-names>M.</given-names></name>
<name><surname>Notter</surname><given-names>T.</given-names></name>
<name><surname>Quitzau</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo-controlled trial</article-title>. <source>Lancet</source> <volume>364</volume>: <fpage>347</fpage>–<lpage>354</lpage>.</citation>
</ref>
<ref id="bibr3-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>R.</given-names></name>
<name><surname>Smerup</surname><given-names>M.</given-names></name>
<name><surname>Sanchez-Quintana</surname><given-names>D.</given-names></name>
<name><surname>Loukas</surname><given-names>M.</given-names></name>
<name><surname>Lunkenheimer</surname><given-names>P.</given-names></name>
</person-group> (<year>2009</year>) <article-title>The three-dimensional arrangement of the myocytes in the ventricular walls</article-title>. <source>Clin Anat</source> <volume>22</volume>: <fpage>64</fpage>–<lpage>76</lpage>.</citation>
</ref>
<ref id="bibr4-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aronson</surname><given-names>D.</given-names></name>
<name><surname>Eitan</surname><given-names>A.</given-names></name>
<name><surname>Dragu</surname><given-names>R.</given-names></name>
<name><surname>Burger</surname><given-names>A.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Relationship between reactive pulmonary hypertension and mortality in patients with acute decompensated heart failure</article-title>. <source>Circ: Heart Failure</source> <volume>4</volume>: <fpage>644</fpage>–<lpage>650</lpage>.</citation>
</ref>
<ref id="bibr5-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Arques</surname><given-names>S.</given-names></name>
<name><surname>Roux</surname><given-names>E.</given-names></name>
<name><surname>Luccioni</surname><given-names>R.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Current clinical applications of spectral tissue Doppler echocardiography (E/E’ ratio) as a noninvasive surrogate for left ventricular diastolic pressures in the diagnosis of heart failure with preserved left ventricular systolic function</article-title>. <source>Cardiovasc Ultrasound</source> <volume>5</volume>:<fpage>16</fpage>.</citation>
</ref>
<ref id="bibr6-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Auricchio</surname><given-names>A.</given-names></name>
<name><surname>Schillinger</surname><given-names>W.</given-names></name>
<name><surname>Meyer</surname><given-names>S.</given-names></name>
<name><surname>Maisano</surname><given-names>F.</given-names></name>
<name><surname>Hoffmann</surname><given-names>R.</given-names></name>
<name><surname>Ussia</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling</article-title>. <source>J Am Coll Cardiol</source> <volume>58</volume>: <fpage>2183</fpage>–<lpage>2189</lpage>.</citation>
</ref>
<ref id="bibr7-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Aurigemma</surname><given-names>G.</given-names></name>
<name><surname>Gaasch</surname><given-names>W.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Clinical practice. Diastolic heart failure</article-title>. <source>N Engl J Med</source> <volume>351</volume>: <fpage>1097</fpage>–<lpage>1105</lpage>.</citation>
</ref>
<ref id="bibr8-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Badesch</surname><given-names>D.B.</given-names></name>
<name><surname>Champion</surname><given-names>H.C.</given-names></name>
<name><surname>Sanchez</surname><given-names>M.A.</given-names></name>
<name><surname>Hoeper</surname><given-names>M.M.</given-names></name>
<name><surname>Loyd</surname><given-names>J.E.</given-names></name>
<name><surname>Manes</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Diagnosis and assessment of pulmonary arterial hypertension</article-title>. <source>J Am Coll Cardiol</source> <volume>54</volume>: <fpage>S55</fpage>–<lpage>S66</lpage>.</citation>
</ref>
<ref id="bibr9-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Barbieri</surname><given-names>A.</given-names></name>
<name><surname>Bursi</surname><given-names>F.</given-names></name>
<name><surname>Grigioni</surname><given-names>F.</given-names></name>
<name><surname>Tribouilloy</surname><given-names>C.</given-names></name>
<name><surname>Avierinos</surname><given-names>J.F.</given-names></name>
<name><surname>Michelena</surname><given-names>H.I.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Prognostic and therapeutic implications of pulmonary hypertension complicating degenerative mitral regurgitation due to flail leaflet: a multicenter long-term international study</article-title>. <source>Eur Heart J</source> <volume>32</volume>: <fpage>751</fpage>–<lpage>759</lpage>.</citation>
</ref>
<ref id="bibr10-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Beyersdorf</surname><given-names>F.</given-names></name>
<name><surname>Schlensak</surname><given-names>C.</given-names></name>
<name><surname>Berchtold-Herz</surname><given-names>M.</given-names></name>
<name><surname>Trummer</surname><given-names>G.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Regression of ‘fixed’ pulmonary vascular resistance in heart transplant candidates after unloading with ventricular assist devices</article-title>. <source>J Thorac Cardiovasc Surg</source> <volume>140</volume>: <fpage>747</fpage>–<lpage>749</lpage>.</citation>
</ref>
<ref id="bibr11-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bhella</surname><given-names>P.</given-names></name>
<name><surname>Pacini</surname><given-names>E.</given-names></name>
<name><surname>Prasad</surname><given-names>A.</given-names></name>
<name><surname>Hastings</surname><given-names>J.</given-names></name>
<name><surname>Adams-Huet</surname><given-names>B.</given-names></name>
<name><surname>Thomas</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Echocardiographic indices do not reliably track changes in left-sided filling pressure in healthy subjects or patients with heart failure with preserved ejection fraction</article-title>. <source>Circ Cardiovasc Imaging</source> <volume>4</volume>: <fpage>482</fpage>–<lpage>489</lpage>.</citation>
</ref>
<ref id="bibr12-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bleeker</surname><given-names>G.</given-names></name>
<name><surname>Schalij</surname><given-names>M.</given-names></name>
<name><surname>Nihoyannopoulos</surname><given-names>P.</given-names></name>
<name><surname>Steendijk</surname><given-names>P.</given-names></name>
<name><surname>Molhoek</surname><given-names>S.</given-names></name>
<name><surname>van Erven</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Left ventricular dyssynchrony predicts right ventricular remodeling after cardiac resynchronization therapy</article-title>. <source>J Am Coll Cardiol</source> <volume>46</volume>: <fpage>2264</fpage>–<lpage>2269</lpage>.</citation>
</ref>
<ref id="bibr13-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonow</surname><given-names>R.</given-names></name>
<name><surname>Carabello</surname><given-names>B.</given-names></name>
<name><surname>Chatterjee</surname><given-names>K.</given-names></name>
<name><surname>de Leon</surname><given-names>A.</given-names><suffix>Jr</suffix></name>
<name><surname>Faxon</surname><given-names>D.</given-names></name>
<name><surname>Freed</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>2008 focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease</article-title>. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease). Endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <source>J Am Coll Cardiol</source> <volume>52</volume>: <fpage>e1</fpage>–<lpage>142</lpage>.</citation>
</ref>
<ref id="bibr14-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonow</surname><given-names>R.</given-names></name>
<name><surname>Carabello</surname><given-names>B.</given-names></name>
<name><surname>Kanu</surname><given-names>C.</given-names></name>
<name><surname>de Groote</surname><given-names>L.</given-names><suffix>Jr</suffix></name>
<name><surname>Faxon</surname><given-names>D.</given-names></name>
<name><surname>Freed</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>ACC/AHA 2006 guidelines for the management of patients with valvular heart disease</article-title>. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 1998 Guidelines for the Management of Patients with Valvular Heart Disease). Developed in collaboration with the Society of Cardiovascular Anesthesiologists. Endorsed by the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons. <source>Circulation</source> <volume>114</volume>: <fpage>e84</fpage>–<lpage>e231</lpage>.</citation>
</ref>
<ref id="bibr15-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braun</surname><given-names>S.</given-names></name>
<name><surname>Schrotter</surname><given-names>H.</given-names></name>
<name><surname>Schmeisser</surname><given-names>A.</given-names></name>
<name><surname>Strasser</surname><given-names>R.H.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Evaluation of pulmonary vascular response to inhaled iloprost in heart transplant candidates with pulmonary venous hypertension</article-title>. <source>Int J Cardiol</source> <volume>115</volume>: <fpage>67</fpage>–<lpage>72</lpage>.</citation>
</ref>
<ref id="bibr16-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Braunwald</surname><given-names>E.</given-names></name>
<name><surname>Braunwald</surname><given-names>N.</given-names></name>
<name><surname>Ross</surname><given-names>J.</given-names><suffix>Jr</suffix></name>
<name><surname>Morrow</surname><given-names>A.</given-names></name>
</person-group> (<year>1965</year>) <article-title>Effects of mitral-valve replacement on the pulmonary vascular dynamics of patients with pulmonary hypertension</article-title>. <source>N Engl J Med</source> <volume>273</volume>: <fpage>509</fpage>–<lpage>514</lpage>.</citation>
</ref>
<ref id="bibr17-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Budhiraja</surname><given-names>R.</given-names></name>
<name><surname>Tuder</surname><given-names>R.</given-names></name>
<name><surname>Hassoun</surname><given-names>P.</given-names></name>
</person-group> (<year>2004</year>) <article-title>Endothelial dysfunction in pulmonary hypertension</article-title>. <source>Circulation</source> <volume>109</volume>: <fpage>159</fpage>–<lpage>165</lpage>.</citation>
</ref>
<ref id="bibr18-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bursi</surname><given-names>F.</given-names></name>
<name><surname>McNallan</surname><given-names>S.</given-names></name>
<name><surname>Redfield</surname><given-names>M.</given-names></name>
<name><surname>Nkomo</surname><given-names>V.</given-names></name>
<name><surname>Lam</surname><given-names>C.</given-names></name>
<name><surname>Weston</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Pulmonary pressures and death in heart failure: a community study</article-title>. <source>J Am Coll Cardiol</source> <volume>59</volume>: <fpage>222</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr19-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Califf</surname><given-names>R.</given-names></name>
<name><surname>Adams</surname><given-names>K.</given-names></name>
<name><surname>McKenna</surname><given-names>W.</given-names></name>
<name><surname>Gheorghiade</surname><given-names>M.</given-names></name>
<name><surname>Uretsky</surname><given-names>B.</given-names></name>
<name><surname>McNulty</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>A randomized controlled trial of epoprostenol therapy for severe congestive heart failure: The Flolan International Randomized Survival Trial (FIRST)</article-title>. <source>Am Heart J</source> <volume>134</volume>: <fpage>44</fpage>–<lpage>54</lpage>.</citation>
</ref>
<ref id="bibr20-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cappola</surname><given-names>T.</given-names></name>
<name><surname>Felker</surname><given-names>G.</given-names></name>
<name><surname>Kao</surname><given-names>W.</given-names></name>
<name><surname>Hare</surname><given-names>J.</given-names></name>
<name><surname>Baughman</surname><given-names>K.</given-names></name>
<name><surname>Kasper</surname><given-names>E.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Pulmonary hypertension and risk of death in cardiomyopathy: patients with myocarditis are at higher risk</article-title>. <source>Circulation</source> <volume>105</volume>: <fpage>1663</fpage>–<lpage>1668</lpage>.</citation>
</ref>
<ref id="bibr21-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Champion</surname><given-names>H.</given-names></name>
<name><surname>Michelakis</surname><given-names>E.</given-names></name>
<name><surname>Hassoun</surname><given-names>P.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Comprehensive invasive and noninvasive approach to the right ventricle-pulmonary circulation unit: state of the art and clinical and research implications</article-title>. <source>Circulation</source> <volume>120</volume>: <fpage>992</fpage>–<lpage>1007</lpage>.</citation>
</ref>
<ref id="bibr22-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chang</surname><given-names>P.</given-names></name>
<name><surname>Longenecker</surname><given-names>J.</given-names></name>
<name><surname>Wang</surname><given-names>N.</given-names></name>
<name><surname>Baughman</surname><given-names>K.</given-names></name>
<name><surname>Conte</surname><given-names>J.</given-names></name>
<name><surname>Hare</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Mild vs severe pulmonary hypertension before heart transplantation: different effects on posttransplantation pulmonary hypertension and mortality</article-title>. <source>J Heart Lung Transplant</source> <volume>24</volume>: <fpage>998</fpage>–<lpage>1007</lpage>.</citation>
</ref>
<ref id="bibr23-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chen</surname><given-names>Y.</given-names></name>
<name><surname>Guo</surname><given-names>H.</given-names></name>
<name><surname>Xu</surname><given-names>D.</given-names></name>
<name><surname>Xu</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Hu</surname><given-names>X.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease</article-title>. <source>Hypertension</source> <volume>59</volume>: <fpage>1170</fpage>–<lpage>1178</lpage>.</citation>
</ref>
<ref id="bibr24-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cody</surname><given-names>R.</given-names></name>
<name><surname>Haas</surname><given-names>G.</given-names></name>
<name><surname>Binkley</surname><given-names>P.</given-names></name>
<name><surname>Capers</surname><given-names>Q.</given-names></name>
<name><surname>Kelley</surname><given-names>R.</given-names></name>
</person-group> (<year>1992</year>) <article-title>Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure</article-title>. <source>Circulation</source> <volume>85</volume>: <fpage>504</fpage>–<lpage>509</lpage>.</citation>
</ref>
<ref id="bibr25-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cooper</surname><given-names>C.</given-names></name>
<name><surname>Jevnikar</surname><given-names>F.</given-names></name>
<name><surname>Walsh</surname><given-names>T.</given-names></name>
<name><surname>Dickinson</surname><given-names>J.</given-names></name>
<name><surname>Mouhaffel</surname><given-names>A.</given-names></name>
<name><surname>Selwyn</surname><given-names>A.</given-names></name>
</person-group> (<year>1998</year>) <article-title>The influence of basal nitric oxide activity on pulmonary vascular resistance in patients with congestive heart failure</article-title>. <source>Am J Cardiol</source> <volume>82</volume>: <fpage>609</fpage>–<lpage>614</lpage>.</citation>
</ref>
<ref id="bibr26-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Damy</surname><given-names>T.</given-names></name>
<name><surname>Goode</surname><given-names>K.</given-names></name>
<name><surname>Kallvikbacka-Bennett</surname><given-names>A.</given-names></name>
<name><surname>Lewinter</surname><given-names>C.</given-names></name>
<name><surname>Hobkirk</surname><given-names>J.</given-names></name>
<name><surname>Nikitin</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Determinants and prognostic value of pulmonary arterial pressure in patients with chronic heart failure</article-title>. <source>Eur Heart J</source> <volume>31</volume>: <fpage>2280</fpage>–<lpage>2290</lpage>.</citation>
</ref>
<ref id="bibr27-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Groote</surname><given-names>J.</given-names></name>
<name><surname>Kirkels</surname><given-names>J.</given-names></name>
<name><surname>Klopping</surname><given-names>C.</given-names></name>
<name><surname>Lahpor</surname><given-names>J.</given-names></name>
<name><surname>Caliskan</surname><given-names>K.</given-names></name>
<name><surname>Maat</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Guidelines for heart transplantation</article-title>. <source>Neth Heart J</source> <volume>16</volume>: <fpage>79</fpage>–<lpage>87</lpage>.</citation>
</ref>
<ref id="bibr28-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>de Groote</surname><given-names>P.</given-names></name>
<name><surname>Fertin</surname><given-names>M.</given-names></name>
<name><surname>Goeminne</surname><given-names>C.</given-names></name>
<name><surname>Petyt</surname><given-names>G.</given-names></name>
<name><surname>Peyrot</surname><given-names>S.</given-names></name>
<name><surname>Foucher-Hossein</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Right ventricular systolic function for risk stratification in patients with stable left ventricular systolic dysfunction: comparison of radionuclide angiography to echoDoppler parameters</article-title>. <source>Eur Heart J</source> <volume>33</volume>(<issue>21</issue>): <fpage>2672</fpage>–<lpage>2679</lpage>.</citation>
</ref>
<ref id="bibr29-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delgado</surname><given-names>J.</given-names></name>
<name><surname>Conde</surname><given-names>E.</given-names></name>
<name><surname>Sanchez</surname><given-names>V.</given-names></name>
<name><surname>Lopez-Rios</surname><given-names>F.</given-names></name>
<name><surname>Gomez-Sanchez</surname><given-names>M.</given-names></name>
<name><surname>Escribano</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Pulmonary vascular remodeling in pulmonary hypertension due to chronic heart failure</article-title>. <source>Eur J Heart Failure</source> <volume>7</volume>: <fpage>1011</fpage>–<lpage>1016</lpage>.</citation>
</ref>
<ref id="bibr30-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Vita</surname><given-names>S.</given-names></name>
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Oreglia</surname><given-names>J.</given-names></name>
<name><surname>Guazzi</surname><given-names>M</given-names></name>
</person-group>. (<year>2002</year>) <article-title>[Alveolar-capillary dysfunction in heart failure]</article-title>. <source>Ital Heart J Suppl</source> <volume>3</volume>: <fpage>1022</fpage>–<lpage>1026</lpage>.</citation>
</ref>
<ref id="bibr31-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Di Salvo</surname><given-names>T.</given-names></name>
<name><surname>Mathier</surname><given-names>M.</given-names></name>
<name><surname>Semigran</surname><given-names>M.</given-names></name>
<name><surname>Dec</surname><given-names>G</given-names></name>
</person-group>. (<year>1995</year>) <article-title>Preserved right ventricular ejection fraction predicts exercise capacity and survival in advanced heart failure</article-title>. <source>J Am Coll Cardiol</source> <volume>25</volume>: <fpage>1143</fpage>–<lpage>1153</lpage>.</citation>
</ref>
<ref id="bibr32-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Dokainish</surname><given-names>H.</given-names></name>
<name><surname>Nguyen</surname><given-names>J.</given-names></name>
<name><surname>Sengupta</surname><given-names>R.</given-names></name>
<name><surname>Pillai</surname><given-names>M.</given-names></name>
<name><surname>Alam</surname><given-names>M.</given-names></name>
<name><surname>Bobek</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Do additional echocardiographic variables increase the accuracy of E/e’ for predicting left ventricular filling pressure in normal ejection fraction? An echocardiographic and invasive hemodynamic study</article-title>. <source>J Am Soc Echocardiogr</source> <volume>23</volume>: <fpage>156</fpage>–<lpage>161</lpage>.</citation>
</ref>
<ref id="bibr33-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Drazner</surname><given-names>M.</given-names></name>
<name><surname>Hamilton</surname><given-names>M.</given-names></name>
<name><surname>Fonarow</surname><given-names>G.</given-names></name>
<name><surname>Creaser</surname><given-names>J.</given-names></name>
<name><surname>Flavell</surname><given-names>C.</given-names></name>
<name><surname>Stevenson</surname><given-names>L.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Relationship between right and left-sided filling pressures in 1000 patients with advanced heart failure</article-title>. <source>J Heart Lung Transplant</source> <volume>18</volume>: <fpage>1126</fpage>–<lpage>1132</lpage>.</citation>
</ref>
<ref id="bibr34-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Enriquez-Sarano</surname><given-names>M.</given-names></name>
<name><surname>Rossi</surname><given-names>A.</given-names></name>
<name><surname>Seward</surname><given-names>J.</given-names></name>
<name><surname>Bailey</surname><given-names>K.</given-names></name>
<name><surname>Tajik</surname><given-names>A.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Determinants of pulmonary hypertension in left ventricular dysfunction</article-title>. <source>J Am Coll Cardiol</source> <volume>29</volume>: <fpage>153</fpage>–<lpage>159</lpage>.</citation>
</ref>
<ref id="bibr35-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Etz</surname><given-names>C.</given-names></name>
<name><surname>Welp</surname><given-names>H.</given-names></name>
<name><surname>Tjan</surname><given-names>T.</given-names></name>
<name><surname>Hoffmeier</surname><given-names>A.</given-names></name>
<name><surname>Weigang</surname><given-names>E.</given-names></name>
<name><surname>Scheld</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Medically refractory pulmonary hypertension: treatment with nonpulsatile left ventricular assist devices</article-title>. <source>Ann Thorac Surg</source> <volume>83</volume>: <fpage>1697</fpage>–<lpage>1705</lpage>.</citation>
</ref>
<ref id="bibr36-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Faggiano</surname><given-names>P.</given-names></name>
<name><surname>Antonini-Canterin</surname><given-names>F.</given-names></name>
<name><surname>Ribichini</surname><given-names>F.</given-names></name>
<name><surname>D’Aloia</surname><given-names>A.</given-names></name>
<name><surname>Ferrero</surname><given-names>V.</given-names></name>
<name><surname>Cervesato</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Pulmonary artery hypertension in adult patients with symptomatic valvular aortic stenosis</article-title>. <source>Am J Cardiol</source> <volume>85</volume>: <fpage>204</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr37-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Felker</surname><given-names>G.</given-names></name>
<name><surname>O’Connor</surname><given-names>C.</given-names></name>
</person-group> (<year>2001a</year>) <article-title>Inotropic therapy for heart failure: an evidence-based approach</article-title>. <source>Am Heart J</source> <volume>142</volume>:<fpage>393</fpage>–<lpage>401</lpage>.</citation>
</ref>
<ref id="bibr38-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Felker</surname><given-names>G.</given-names></name>
<name><surname>O’Connor</surname><given-names>C.</given-names></name>
</person-group> (<year>2001b</year>) <article-title>Rational use of inotropic therapy in heart failure</article-title>. <source>Curr Cardiol Rep</source> <volume>3</volume>: <fpage>108</fpage>–<lpage>113</lpage>.</citation>
</ref>
<ref id="bibr39-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fisher</surname><given-names>M.</given-names></name>
<name><surname>Forfia</surname><given-names>P.</given-names></name>
<name><surname>Chamera</surname><given-names>E.</given-names></name>
<name><surname>Housten-Harris</surname><given-names>T.</given-names></name>
<name><surname>Champion</surname><given-names>H.</given-names></name>
<name><surname>Girgis</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension</article-title>. <source>Am J Respir Crit Care Med</source> <volume>179</volume>: <fpage>615</fpage>–<lpage>621</lpage>.</citation>
</ref>
<ref id="bibr40-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Franzen</surname><given-names>O.</given-names></name>
<name><surname>van der Heyden</surname><given-names>J.</given-names></name>
<name><surname>Baldus</surname><given-names>S.</given-names></name>
<name><surname>Schluter</surname><given-names>M.</given-names></name>
<name><surname>Schillinger</surname><given-names>W.</given-names></name>
<name><surname>Butter</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>MitraClip© therapy in patients with end-stage systolic heart failure</article-title>. <source>Eur J Heart Failure</source> <volume>13</volume>: <fpage>569</fpage>–<lpage>576</lpage>.</citation>
</ref>
<ref id="bibr41-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gaemperli</surname><given-names>O.</given-names></name>
<name><surname>Moccetti</surname><given-names>M.</given-names></name>
<name><surname>Surder</surname><given-names>D.</given-names></name>
<name><surname>Biaggi</surname><given-names>P.</given-names></name>
<name><surname>Hurlimann</surname><given-names>D.</given-names></name>
<name><surname>Kretschmar</surname><given-names>O.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Acute haemodynamic changes after percutaneous mitral valve repair: relation to mid-term outcomes</article-title>. <source>Heart</source> <volume>98</volume>: <fpage>126</fpage>–<lpage>132</lpage>.</citation>
</ref>
<ref id="bibr42-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Galie</surname><given-names>N.</given-names></name>
<name><surname>Hoeper</surname><given-names>M.</given-names></name>
<name><surname>Humbert</surname><given-names>M.</given-names></name>
<name><surname>Torbicki</surname><given-names>A.</given-names></name>
<name><surname>Vachiery</surname><given-names>J.</given-names></name>
<name><surname>Barbera</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Guidelines for the diagnosis and treatment of pulmonary hypertension. The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Endorsed by the International Society of Heart and Lung Transplantation (ISHLT)</article-title>. <source>Eur Heart J</source> <volume>30</volume>: <fpage>2493</fpage>–<lpage>2537</lpage>.</citation>
</ref>
<ref id="bibr43-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghio</surname><given-names>S.</given-names></name>
<name><surname>Gavazzi</surname><given-names>A.</given-names></name>
<name><surname>Campana</surname><given-names>C.</given-names></name>
<name><surname>Inserra</surname><given-names>C.</given-names></name>
<name><surname>Klersy</surname><given-names>C.</given-names></name>
<name><surname>Sebastiani</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Independent and additive prognostic value of right ventricular systolic function and pulmonary artery pressure in patients with chronic heart failure</article-title>. <source>J Am Coll Cardiol</source> <volume>37</volume>: <fpage>183</fpage>–<lpage>188</lpage>.</citation>
</ref>
<ref id="bibr44-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giaid</surname><given-names>A.</given-names></name>
<name><surname>Saleh</surname><given-names>D.</given-names></name>
</person-group> (<year>1995</year>) <article-title>Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension</article-title>. <source>N Engl J Med</source> <volume>333</volume>: <fpage>214</fpage>–<lpage>221</lpage>.</citation>
</ref>
<ref id="bibr45-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giaid</surname><given-names>A.</given-names></name>
<name><surname>Yanagisawa</surname><given-names>M.</given-names></name>
<name><surname>Langleben</surname><given-names>D.</given-names></name>
<name><surname>Michel</surname><given-names>R.</given-names></name>
<name><surname>Levy</surname><given-names>R.</given-names></name>
<name><surname>Shennib</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>1993</year>) <article-title>Expression of endothelin-1 in the lungs of patients with pulmonary hypertension</article-title>. <source>N Engl J Med</source> <volume>328</volume>: <fpage>1732</fpage>–<lpage>1739</lpage>.</citation>
</ref>
<ref id="bibr46-1753944713477518">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Grunig</surname><given-names>E.</given-names></name>
<name><surname>Barner</surname><given-names>A.</given-names></name>
<name><surname>Bell</surname><given-names>M.</given-names></name>
<name><surname>Claussen</surname><given-names>M.</given-names></name>
<name><surname>Dandel</surname><given-names>M.</given-names></name>
<name><surname>Dumitrescu</surname><given-names>D</given-names></name><etal/>
</person-group>. <italic>et al</italic>. (<year>2011</year>) <article-title>Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011</article-title>. <source>Int J Cardiol</source> <volume>154</volume>(<supplement>Suppl. 1</supplement>): <fpage>S3</fpage>–<lpage>12</lpage>.</citation>
</ref>
<ref id="bibr47-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Arena</surname><given-names>R.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Pulmonary hypertension with left-sided heart disease</article-title>. <source>Nat Rev Cardiol</source> <volume>7</volume>: <fpage>648</fpage>–<lpage>659</lpage>.</citation>
</ref>
<ref id="bibr48-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Boracchi</surname><given-names>P.</given-names></name>
<name><surname>Labate</surname><given-names>V.</given-names></name>
<name><surname>Arena</surname><given-names>R.</given-names></name>
<name><surname>Reina</surname><given-names>G.</given-names></name>
</person-group> (<year>2012a</year>) <article-title>Exercise oscillatory breathing and NT-proBNP levels in stable heart failure provide the strongest prediction of cardiac outcome when combining biomarkers with cardiopulmonary exercise testing</article-title>. <source>J Card Failure</source> <volume>18</volume>: <fpage>313</fpage>–<lpage>320</lpage>.</citation>
</ref>
<ref id="bibr49-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Borlaug</surname><given-names>B.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Pulmonary hypertension due to left heart disease</article-title>. <source>Circulation</source> <volume>126</volume>: <fpage>975</fpage>–<lpage>990</lpage>.</citation>
</ref>
<ref id="bibr50-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Casali</surname><given-names>M.</given-names></name>
<name><surname>Berti</surname><given-names>F.</given-names></name>
<name><surname>Rossoni</surname><given-names>G.</given-names></name>
<name><surname>Colonna</surname><given-names>V.</given-names></name>
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Endothelium-mediated modulation of ergoreflex and improvement in exercise ventilation by acute sildenafil in heart failure patients</article-title>. <source>Clin Pharmacol Ther</source> <volume>83</volume>: <fpage>336</fpage>–<lpage>341</lpage>.</citation>
</ref>
<ref id="bibr51-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Myers</surname><given-names>J.</given-names></name>
<name><surname>Arena</surname><given-names>R.</given-names></name>
</person-group> (<year>2005</year>) <article-title>Cardiopulmonary exercise testing in the clinical and prognostic assessment of diastolic heart failure</article-title>. <source>J Am Coll Cardiol</source> <volume>46</volume>:<fpage>1883</fpage>–<lpage>1890</lpage>.</citation>
</ref>
<ref id="bibr52-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Pontone</surname><given-names>G.</given-names></name>
<name><surname>Brambilla</surname><given-names>R.</given-names></name>
<name><surname>Agostoni</surname><given-names>P.</given-names></name>
<name><surname>Reina</surname><given-names>G.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Alveolar–capillary membrane gas conductance: a novel prognostic indicator in chronic heart failure</article-title>. <source>Eur Heart J</source> <volume>23</volume>: <fpage>467</fpage>–<lpage>476</lpage>.</citation>
</ref>
<ref id="bibr53-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Samaja</surname><given-names>M.</given-names></name>
<name><surname>Arena</surname><given-names>R.</given-names></name>
<name><surname>Vicenzi</surname><given-names>M.</given-names></name>
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
</person-group> (<year>2007</year>) <article-title>Long-term use of sildenafil in the therapeutic management of heart failure</article-title>. <source>J Am Coll Cardiol</source> <volume>50</volume>: <fpage>2136</fpage>–<lpage>2144</lpage>.</citation>
</ref>
<ref id="bibr54-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Tumminello</surname><given-names>G.</given-names></name>
<name><surname>Di Marco</surname><given-names>F.</given-names></name>
<name><surname>Fiorentini</surname><given-names>C.</given-names></name>
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
</person-group> (<year>2004</year>) <article-title>The effects of phosphodiesterase-5 inhibition with sildenafil on pulmonary hemodynamics and diffusion capacity, exercise ventilatory efficiency, and oxygen uptake kinetics in chronic heart failure</article-title>. <source>J Am Coll Cardiol</source> <volume>44</volume>: <fpage>2339</fpage>–<lpage>2348</lpage>.</citation>
</ref>
<ref id="bibr55-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Vicenzi</surname><given-names>M.</given-names></name>
<name><surname>Arena</surname><given-names>R.</given-names></name>
</person-group> (<year>2012b</year>) <article-title>Phosphodiesterase 5 inhibition with sildenafil reverses exercise oscillatory breathing in chronic heart failure: a long-term cardiopulmonary exercise testing placebo-controlled study</article-title>. <source>Eur J Heart Failure</source> <volume>14</volume>: <fpage>82</fpage>–<lpage>90</lpage>.</citation>
</ref>
<ref id="bibr56-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
<name><surname>Vicenzi</surname><given-names>M.</given-names></name>
<name><surname>Arena</surname><given-names>R.</given-names></name>
<name><surname>Guazzi</surname><given-names>M.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Pulmonary hypertension in heart failure with preserved ejection fraction: a target of phosphodiesterase-5 inhibition in a 1-year study</article-title>. <source>Circulation</source> <volume>124</volume>: <fpage>164</fpage>–<lpage>174</lpage>.</citation>
</ref>
<ref id="bibr57-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haddad</surname><given-names>F.</given-names></name>
<name><surname>Doyle</surname><given-names>R.</given-names></name>
<name><surname>Murphy</surname><given-names>D.</given-names></name>
<name><surname>Hunt</surname><given-names>S.</given-names></name>
</person-group> (<year>2008a</year>) <article-title>Right ventricular function in cardiovascular disease, part II: pathophysiology, clinical importance, and management of right ventricular failure</article-title>. <source>Circulation</source> <volume>117</volume>: <fpage>1717</fpage>–<lpage>1731</lpage>.</citation>
</ref>
<ref id="bibr58-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haddad</surname><given-names>F.</given-names></name>
<name><surname>Hunt</surname><given-names>S.</given-names></name>
<name><surname>Rosenthal</surname><given-names>D.</given-names></name>
<name><surname>Murphy</surname><given-names>D.</given-names></name>
</person-group> (<year>2008b</year>) <article-title>Right ventricular function in cardiovascular disease. Part I: Anatomy, physiology, aging, and functional assessment of the right ventricle</article-title>. <source>Circulation</source> <volume>117</volume>: <fpage>1436</fpage>–<lpage>1448</lpage>.</citation>
</ref>
<ref id="bibr59-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Haddad</surname><given-names>F.</given-names></name>
<name><surname>Kudelko</surname><given-names>K.</given-names></name>
<name><surname>Mercier</surname><given-names>O.</given-names></name>
<name><surname>Vrtovec</surname><given-names>B.</given-names></name>
<name><surname>Zamanian</surname><given-names>R.</given-names></name>
<name><surname>de Jesus Perez</surname><given-names>V.</given-names></name>
</person-group> (<year>2011</year>) <article-title>Pulmonary hypertension associated with left heart disease: characteristics, emerging concepts, and treatment strategies</article-title>. <source>Prog Cardiovasc Dis</source> <volume>54</volume>: <fpage>154</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr60-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hart</surname><given-names>S.</given-names></name>
<name><surname>Krasuski</surname><given-names>R.</given-names></name>
<name><surname>Wang</surname><given-names>A.</given-names></name>
<name><surname>Kisslo</surname><given-names>K.</given-names></name>
<name><surname>Harrison</surname><given-names>J.</given-names></name>
<name><surname>Bashore</surname><given-names>T.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Pulmonary hypertension and elevated transpulmonary gradient in patients with mitral stenosis</article-title>. <source>J Heart Valve Dis</source> <volume>19</volume>: <fpage>708</fpage>–<lpage>715</lpage>.</citation>
</ref>
<ref id="bibr61-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Harvey</surname><given-names>R.</given-names></name>
<name><surname>Enson</surname><given-names>Y.</given-names></name>
<name><surname>Ferrer</surname><given-names>M.</given-names></name>
</person-group> (<year>1971</year>) <article-title>A reconsideration of the origins of pulmonary hypertension</article-title>. <source>Chest</source> <volume>59</volume>: <fpage>82</fpage>–<lpage>94</lpage>.</citation>
</ref>
<ref id="bibr62-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ho</surname><given-names>J.</given-names></name>
<name><surname>Gona</surname><given-names>P.</given-names></name>
<name><surname>Pencina</surname><given-names>M.</given-names></name>
<name><surname>Tu</surname><given-names>J.</given-names></name>
<name><surname>Austin</surname><given-names>P.</given-names></name>
<name><surname>Vasan</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Discriminating clinical features of heart failure with preserved vs. reduced ejection fraction in the community</article-title>. <source>Eur Heart J</source> <volume>33</volume>: <fpage>1734</fpage>–<lpage>1741</lpage>.</citation>
</ref>
<ref id="bibr63-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoeper</surname><given-names>M.</given-names></name>
<name><surname>Barbera</surname><given-names>J.</given-names></name>
<name><surname>Channick</surname><given-names>R.</given-names></name>
<name><surname>Hassoun</surname><given-names>P.</given-names></name>
<name><surname>Lang</surname><given-names>I.</given-names></name>
<name><surname>Manes</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension</article-title>. <source>J Am Coll Cardiol</source> <volume>54</volume>: <fpage>S85</fpage>–<lpage>S96</lpage>.</citation>
</ref>
<ref id="bibr64-1753944713477518">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Howlett</surname><given-names>J.</given-names></name>
<name><surname>McKelvie</surname><given-names>R.</given-names></name>
<name><surname>Arnold</surname><given-names>J.</given-names></name>
<name><surname>Costigan</surname><given-names>J.</given-names></name>
<name><surname>Dorian</surname><given-names>P.</given-names></name>
<name><surname>Ducharme</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials</article-title>. <source>Can J Cardiol</source> <volume>25</volume>: <fpage>85</fpage>–<lpage>105</lpage>.</citation>
</ref>
<ref id="bibr65-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ilsar</surname><given-names>R.</given-names></name>
<name><surname>Bailey</surname><given-names>B.</given-names></name>
<name><surname>Dobbins</surname><given-names>T.</given-names></name>
<name><surname>Celermajer</surname><given-names>D.</given-names></name>
</person-group> (<year>2010</year>) <article-title>The relationship between pulmonary artery and pulmonary capillary wedge pressure for the diagnosis of pulmonary vascular disease</article-title>. <source>Heart Lung Circ</source> <volume>19</volume>: <fpage>38</fpage>–<lpage>42</lpage>.</citation>
</ref>
<ref id="bibr66-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Johnson</surname><given-names>L.</given-names></name>
<name><surname>Hapanowicz</surname><given-names>M.</given-names></name>
<name><surname>Buonanno</surname><given-names>C.</given-names></name>
<name><surname>Bowser</surname><given-names>M.</given-names></name>
<name><surname>Marvasti</surname><given-names>M.</given-names></name>
<name><surname>Parker</surname><given-names>F.</given-names><suffix>Jr</suffix></name>
</person-group> (<year>1988</year>) <article-title>Pulmonary hypertension in isolated aortic stenosis. Hemodynamic correlations and follow-up</article-title>. <source>J Thorac Cardiovasc Surg</source> <volume>95</volume>: <fpage>603</fpage>–<lpage>607</lpage>.</citation>
</ref>
<ref id="bibr67-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kalra</surname><given-names>P.</given-names></name>
<name><surname>Moon</surname><given-names>J.</given-names></name>
<name><surname>Coats</surname><given-names>A.</given-names></name>
</person-group> (<year>2002</year>) <article-title>Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?</article-title> <source>Int J Cardiol</source> <volume>85</volume>: <fpage>195</fpage>–<lpage>197</lpage>.</citation>
</ref>
<ref id="bibr68-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kapoor</surname><given-names>N.</given-names></name>
<name><surname>Varadarajan</surname><given-names>P.</given-names></name>
<name><surname>Pai</surname><given-names>R.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Echocardiographic predictors of pulmonary hypertension in patients with severe aortic stenosis</article-title>. <source>Eur J Echocardiogr</source> <volume>9</volume>: <fpage>31</fpage>–<lpage>33</lpage>.</citation>
</ref>
<ref id="bibr69-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katz</surname><given-names>S.</given-names></name>
<name><surname>Balidemaj</surname><given-names>K.</given-names></name>
<name><surname>Homma</surname><given-names>S.</given-names></name>
<name><surname>Wu</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Maybaum</surname><given-names>S.</given-names></name>
</person-group> (<year>2000</year>) <article-title>Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure</article-title>. <source>J Am Coll Cardiol</source> <volume>36</volume>: <fpage>845</fpage>–<lpage>851</lpage>.</citation>
</ref>
<ref id="bibr70-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kerem</surname><given-names>A.</given-names></name>
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Kaestle</surname><given-names>S.</given-names></name>
<name><surname>Hoffmann</surname><given-names>J.</given-names></name>
<name><surname>Schoene</surname><given-names>A.</given-names></name>
<name><surname>Singh</surname><given-names>B.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Lung endothelial dysfunction in congestive heart failure: role of impaired Ca2+ signaling and cytoskeletal reorganization</article-title>. <source>Circ Res</source> <volume>106</volume>: <fpage>1103</fpage>–<lpage>1116</lpage>.</citation>
</ref>
<ref id="bibr71-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khush</surname><given-names>K.</given-names></name>
<name><surname>Tasissa</surname><given-names>G.</given-names></name>
<name><surname>Butler</surname><given-names>J.</given-names></name>
<name><surname>McGlothlin</surname><given-names>D.</given-names></name>
<name><surname>De Marco</surname><given-names>T</given-names></name>
</person-group>. (<year>2009</year>) <article-title>Effect of pulmonary hypertension on clinical outcomes in advanced heart failure: analysis of the Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness (ESCAPE) database</article-title>. <source>Am Heart J</source> <volume>157</volume>: <fpage>1026</fpage>–<lpage>1034</lpage>.</citation>
</ref>
<ref id="bibr72-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kind</surname><given-names>T.</given-names></name>
<name><surname>Mauritz</surname><given-names>G.</given-names></name>
<name><surname>Marcus</surname><given-names>J.</given-names></name>
<name><surname>van de Veerdonk</surname><given-names>N.</given-names></name>
<name><surname>Vonk-Noordegraaf</surname><given-names>A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Right ventricular ejection fraction is better reflected by transverse rather than longitudinal wall motion in pulmonary hypertension</article-title>. <source>J Cardiovasc Magn Reson</source> <volume>12</volume>: <fpage>35</fpage>.</citation>
</ref>
<ref id="bibr73-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kleber</surname><given-names>F.</given-names></name>
<name><surname>Vietzke</surname><given-names>G.</given-names></name>
<name><surname>Wernecke</surname><given-names>K.</given-names></name>
<name><surname>Bauer</surname><given-names>U.</given-names></name>
<name><surname>Opitz</surname><given-names>C.</given-names></name>
<name><surname>Wensel</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Impairment of ventilatory efficiency in heart failure: prognostic impact</article-title>. <source>Circulation</source> <volume>101</volume>: <fpage>2803</fpage>–<lpage>2809</lpage>.</citation>
</ref>
<ref id="bibr74-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kovacs</surname><given-names>G.</given-names></name>
<name><surname>Berghold</surname><given-names>A.</given-names></name>
<name><surname>Scheidl</surname><given-names>S.</given-names></name>
<name><surname>Olschewski</surname><given-names>H.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Pulmonary arterial pressure during rest and exercise in healthy subjects: a systematic review</article-title>. <source>Eur Respir J</source> <volume>34</volume>: <fpage>888</fpage>–<lpage>894</lpage>.</citation>
</ref>
<ref id="bibr75-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kurt</surname><given-names>M.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Torre-Amione</surname><given-names>G.</given-names></name>
<name><surname>Nagueh</surname><given-names>S.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Left atrial function in diastolic heart failure</article-title>. <source>Circ Cardiovasc Imaging</source> <volume>2</volume>: <fpage>10</fpage>–<lpage>15</lpage>.</citation>
</ref>
<ref id="bibr76-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuznetsova</surname><given-names>T.</given-names></name>
<name><surname>Herbots</surname><given-names>L.</given-names></name>
<name><surname>Lopez</surname><given-names>B.</given-names></name>
<name><surname>Jin</surname><given-names>Y.</given-names></name>
<name><surname>Richart</surname><given-names>T.</given-names></name>
<name><surname>Thijs</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Prevalence of left ventricular diastolic dysfunction in a general population</article-title>. <source>Circ Heart Failure</source> <volume>2</volume>: <fpage>105</fpage>–<lpage>112</lpage>.</citation>
</ref>
<ref id="bibr77-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lam</surname><given-names>C.</given-names></name>
<name><surname>Borlaug</surname><given-names>B.</given-names></name>
<name><surname>Kane</surname><given-names>G.</given-names></name>
<name><surname>Enders</surname><given-names>F.</given-names></name>
<name><surname>Rodeheffer</surname><given-names>R.</given-names></name>
<name><surname>Redfield</surname><given-names>M.</given-names></name>
</person-group> (<year>2009a</year>) <article-title>Age-associated increases in pulmonary artery systolic pressure in the general population</article-title>. <source>Circulation</source> <volume>119</volume>: <fpage>2663</fpage>–<lpage>2670</lpage>.</citation>
</ref>
<ref id="bibr78-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lam</surname><given-names>C.</given-names></name>
<name><surname>Roger</surname><given-names>V.</given-names></name>
<name><surname>Rodeheffer</surname><given-names>R.</given-names></name>
<name><surname>Borlaug</surname><given-names>B.</given-names></name>
<name><surname>Enders</surname><given-names>F.</given-names></name>
<name><surname>Redfield</surname><given-names>M.</given-names></name>
</person-group> (<year>2009b</year>) <article-title>Pulmonary hypertension in heart failure with preserved ejection fraction: a community-based study</article-title>. <source>J Am Coll Cardiol</source> <volume>53</volume>: <fpage>1119</fpage>–<lpage>1126</lpage>.</citation>
</ref>
<ref id="bibr79-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lepore</surname><given-names>J.</given-names></name>
<name><surname>Maroo</surname><given-names>A.</given-names></name>
<name><surname>Bigatello</surname><given-names>L.</given-names></name>
<name><surname>Dec</surname><given-names>G.</given-names></name>
<name><surname>Zapol</surname><given-names>W.</given-names></name>
<name><surname>Bloch</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide</article-title>. <source>Chest</source> <volume>127</volume>: <fpage>1647</fpage>–<lpage>1653</lpage>.</citation>
</ref>
<ref id="bibr80-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levine</surname><given-names>M.</given-names></name>
<name><surname>Weinstein</surname><given-names>J.</given-names></name>
<name><surname>Diver</surname><given-names>D.</given-names></name>
<name><surname>Berman</surname><given-names>A.</given-names></name>
<name><surname>Wyman</surname><given-names>R.</given-names></name>
<name><surname>Cunningham</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>1989</year>) <article-title>Progressive improvement in pulmonary vascular resistance after percutaneous mitral valvuloplasty</article-title>. <source>Circulation</source> <volume>79</volume>: <fpage>1061</fpage>–<lpage>1067</lpage>.</citation>
</ref>
<ref id="bibr81-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>G.</given-names></name>
<name><surname>Lachmann</surname><given-names>J.</given-names></name>
<name><surname>Camuso</surname><given-names>J.</given-names></name>
<name><surname>Lepore</surname><given-names>J.</given-names></name>
<name><surname>Shin</surname><given-names>J.</given-names></name>
<name><surname>Martinovic</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2007a</year>) <article-title>Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure</article-title>. <source>Circulation</source> <volume>115</volume>: <fpage>59</fpage>–<lpage>66</lpage>.</citation>
</ref>
<ref id="bibr82-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>G.</given-names></name>
<name><surname>Shah</surname><given-names>R.</given-names></name>
<name><surname>Pappagianopolas</surname><given-names>P.</given-names></name>
<name><surname>Systrom</surname><given-names>D.</given-names></name>
<name><surname>Semigran</surname><given-names>M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Determinants of ventilatory efficiency in heart failure: the role of right ventricular performance and pulmonary vascular tone</article-title>. <source>Circ Heart Failure</source> <volume>1</volume>: <fpage>227</fpage>–<lpage>233</lpage>.</citation>
</ref>
<ref id="bibr83-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lewis</surname><given-names>G.</given-names></name>
<name><surname>Shah</surname><given-names>R.</given-names></name>
<name><surname>Shahzad</surname><given-names>K.</given-names></name>
<name><surname>Camuso</surname><given-names>J.</given-names></name>
<name><surname>Pappagianopoulos</surname><given-names>P.</given-names></name>
<name><surname>Hung</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2007b</year>) <article-title>Sildenafil improves exercise capacity and quality of life in patients with systolic heart failure and secondary pulmonary hypertension</article-title>. <source>Circulation</source> <volume>116</volume>: <fpage>1555</fpage>–<lpage>1562</lpage>.</citation>
</ref>
<ref id="bibr84-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindman</surname><given-names>B.</given-names></name>
<name><surname>Zajarias</surname><given-names>A.</given-names></name>
<name><surname>Madrazo</surname><given-names>J.</given-names></name>
<name><surname>Shah</surname><given-names>J.</given-names></name>
<name><surname>Gage</surname><given-names>B.</given-names></name>
<name><surname>Novak</surname><given-names>E.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Effects of phosphodiesterase type 5 inhibition on systemic and pulmonary hemodynamics and ventricular function in patients with severe symptomatic aortic stenosis</article-title>. <source>Circulation</source> <volume>125</volume>: <fpage>2353</fpage>–<lpage>2362</lpage>.</citation>
</ref>
<ref id="bibr85-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lindqvist</surname><given-names>P.</given-names></name>
<name><surname>Calcutteea</surname><given-names>A.</given-names></name>
<name><surname>Henein</surname><given-names>M.</given-names></name>
</person-group> (<year>2008</year>) <article-title>Echocardiography in the assessment of right heart function</article-title>. <source>Eur J Echocardiogr</source> <volume>9</volume>: <fpage>225</fpage>–<lpage>234</lpage>.</citation>
</ref>
<ref id="bibr86-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Magne</surname><given-names>J.</given-names></name>
<name><surname>Lancellotti</surname><given-names>P.</given-names></name>
<name><surname>Pierard</surname><given-names>L.A.</given-names></name>
</person-group> (<year>2010</year>) <article-title>Exercise pulmonary hypertension in asymptomatic degenerative mitral regurgitation</article-title>. <source>Circulation</source> <volume>122</volume>: <fpage>33</fpage>–<lpage>41</lpage>.</citation>
</ref>
<ref id="bibr87-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Malouf</surname><given-names>J.</given-names></name>
<name><surname>Enriquez-Sarano</surname><given-names>M.</given-names></name>
<name><surname>Pellikka</surname><given-names>P.</given-names></name>
<name><surname>Oh</surname><given-names>J.</given-names></name>
<name><surname>Bailey</surname><given-names>K.</given-names></name>
<name><surname>Chandrasekaran</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Severe pulmonary hypertension in patients with severe aortic valve stenosis: clinical profile and prognostic implications</article-title>. <source>J Am Coll Cardiol</source> <volume>40</volume>: <fpage>789</fpage>–<lpage>795</lpage>.</citation>
</ref>
<ref id="bibr88-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marechaux</surname><given-names>S.</given-names></name>
<name><surname>Neicu</surname><given-names>D.</given-names></name>
<name><surname>Braun</surname><given-names>S.</given-names></name>
<name><surname>Richardson</surname><given-names>M.</given-names></name>
<name><surname>Delsart</surname><given-names>P.</given-names></name>
<name><surname>Bouabdallaoui</surname><given-names>N.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Functional mitral regurgitation: a link to pulmonary hypertension in heart failure with preserved ejection fraction</article-title>. <source>J Card Failure</source> <volume>17</volume>: <fpage>806</fpage>–<lpage>812</lpage>.</citation>
</ref>
<ref id="bibr89-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martin</surname><given-names>J.</given-names></name>
<name><surname>Siegenthaler</surname><given-names>M.</given-names></name>
<name><surname>Friesewinkel</surname><given-names>O.</given-names></name>
<name><surname>Fader</surname><given-names>T.</given-names></name>
<name><surname>van de Loo</surname><given-names>A.</given-names></name>
<name><surname>Trummer</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Implantable left ventricular assist device for treatment of pulmonary hypertension in candidates for orthotopic heart transplantation-a preliminary study</article-title>. <source>Eur J Cardiothorac Surg</source> <volume>25</volume>: <fpage>971</fpage>–<lpage>977</lpage>.</citation>
</ref>
<ref id="bibr90-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McQuillan</surname><given-names>B.</given-names></name>
<name><surname>Picard</surname><given-names>M.</given-names></name>
<name><surname>Leavitt</surname><given-names>M.</given-names></name>
<name><surname>Weyman</surname><given-names>A.</given-names></name>
</person-group> (<year>2001</year>) <article-title>Clinical correlates and reference intervals for pulmonary artery systolic pressure among echocardiographically normal subjects</article-title>. <source>Circulation</source> <volume>104</volume>: <fpage>2797</fpage>–<lpage>2802</lpage>.</citation>
</ref>
<ref id="bibr91-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehra</surname><given-names>M.</given-names></name>
<name><surname>Kobashigawa</surname><given-names>J.</given-names></name>
<name><surname>Starling</surname><given-names>R.</given-names></name>
<name><surname>Russell</surname><given-names>S.</given-names></name>
<name><surname>Uber</surname><given-names>P.</given-names></name>
<name><surname>Parameshwar</surname><given-names>J.</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Listing criteria for heart transplantation: International Society for Heart and Lung Transplantation guidelines for the care of cardiac transplant candidates–2006</article-title>. <source>J Heart Lung Transplant</source> <volume>25</volume>: <fpage>1024</fpage>–<lpage>1042</lpage>.</citation>
</ref>
<ref id="bibr92-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Meyer</surname><given-names>P.</given-names></name>
<name><surname>Filippatos</surname><given-names>G.</given-names></name>
<name><surname>Ahmed</surname><given-names>M.</given-names></name>
<name><surname>Iskandrian</surname><given-names>A.</given-names></name>
<name><surname>Bittner</surname><given-names>V.</given-names></name>
<name><surname>Perry</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Effects of right ventricular ejection fraction on outcomes in chronic systolic heart failure</article-title>. <source>Circulation</source> <volume>121</volume>: <fpage>252</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr93-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mikus</surname><given-names>E.</given-names></name>
<name><surname>Stepanenko</surname><given-names>A.</given-names></name>
<name><surname>Krabatsch</surname><given-names>T.</given-names></name>
<name><surname>Dandel</surname><given-names>M.</given-names></name>
<name><surname>Lehmkuhl</surname><given-names>H.</given-names></name>
<name><surname>Loforte</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2011a</year>) <article-title>Left ventricular assist device or heart transplantation: impact of transpulmonary gradient and pulmonary vascular resistance on decision making</article-title>. <source>Eur J Cardiothorac Surg</source> <volume>39</volume>: <fpage>310</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr94-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mikus</surname><given-names>E.</given-names></name>
<name><surname>Stepanenko</surname><given-names>A.</given-names></name>
<name><surname>Krabatsch</surname><given-names>T.</given-names></name>
<name><surname>Loforte</surname><given-names>A.</given-names></name>
<name><surname>Dandel</surname><given-names>M.</given-names></name>
<name><surname>Lehmkuhl</surname><given-names>H.</given-names></name><etal/>
</person-group>. (<year>2011b</year>) <article-title>Reversibility of fixed pulmonary hypertension in left ventricular assist device support recipients</article-title>. <source>Eur J Cardiothorac Surg</source> <volume>40</volume>: <fpage>971</fpage>–<lpage>977</lpage>.</citation>
</ref>
<ref id="bibr95-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mullens</surname><given-names>W.</given-names></name>
<name><surname>Borowski</surname><given-names>A.</given-names></name>
<name><surname>Curtin</surname><given-names>R.</given-names></name>
<name><surname>Thomas</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>W.</given-names></name>
</person-group> (<year>2009</year>) <article-title>Tissue Doppler imaging in the estimation of intracardiac filling pressure in decompensated patients with advanced systolic heart failure</article-title>. <source>Circulation</source> <volume>119</volume>: <fpage>62</fpage>–<lpage>70</lpage>.</citation>
</ref>
<ref id="bibr96-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Naeije</surname><given-names>R.</given-names></name>
<name><surname>Vachiery</surname><given-names>J.</given-names></name>
<name><surname>Yerly</surname><given-names>P.</given-names></name>
<name><surname>Vanderpool</surname><given-names>R.</given-names></name>
</person-group> (<year>2012</year>) <article-title>The transpulmonary pressure gradient for the diagnosis of pulmonary vascular disease</article-title>. <source>Eur Respir J</source> <volume>41</volume>(<issue>1</issue>): <fpage>217</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr97-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagendran</surname><given-names>J.</given-names></name>
<name><surname>Archer</surname><given-names>S.</given-names></name>
<name><surname>Soliman</surname><given-names>D.</given-names></name>
<name><surname>Gurtu</surname><given-names>V.</given-names></name>
<name><surname>Moudgil</surname><given-names>R.</given-names></name>
<name><surname>Haromy</surname><given-names>A.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Phosphodiesterase type 5 is highly expressed in the hypertrophied human right ventricle, and acute inhibition of phosphodiesterase type 5 improves contractility</article-title>. <source>Circulation</source> <volume>116</volume>: <fpage>238</fpage>–<lpage>248</lpage>.</citation>
</ref>
<ref id="bibr98-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nagueh</surname><given-names>S.</given-names></name>
<name><surname>Middleton</surname><given-names>K.</given-names></name>
<name><surname>Kopelen</surname><given-names>H.</given-names></name>
<name><surname>Zoghbi</surname><given-names>W.</given-names></name>
<name><surname>Quinones</surname><given-names>M.</given-names></name>
</person-group> (<year>1997</year>) <article-title>Doppler tissue imaging: a noninvasive technique for evaluation of left ventricular relaxation and estimation of filling pressures</article-title>. <source>J Am Coll Cardiol</source> <volume>30</volume>: <fpage>1527</fpage>–<lpage>1533</lpage>.</citation>
</ref>
<ref id="bibr99-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Niebauer</surname><given-names>J.</given-names></name>
<name><surname>Volk</surname><given-names>H.</given-names></name>
<name><surname>Kemp</surname><given-names>M.</given-names></name>
<name><surname>Dominguez</surname><given-names>M.</given-names></name>
<name><surname>Schumann</surname><given-names>R.</given-names></name>
<name><surname>Rauchhaus</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Endotoxin and immune activation in chronic heart failure: a prospective cohort study</article-title>. <source>Lancet</source> <volume>353</volume>: <fpage>1838</fpage>–<lpage>1842</lpage>.</citation>
</ref>
<ref id="bibr100-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nielsen</surname><given-names>E.</given-names></name>
<name><surname>Smerup</surname><given-names>M.</given-names></name>
<name><surname>Agger</surname><given-names>P.</given-names></name>
<name><surname>Frandsen</surname><given-names>J.</given-names></name>
<name><surname>Ringgard</surname><given-names>S.</given-names></name>
<name><surname>Pedersen</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Normal right ventricular three-dimensional architecture, as assessed with diffusion tensor magnetic resonance imaging, is preserved during experimentally induced right ventricular hypertrophy</article-title>. <source>Anat Rec</source> (Hoboken ) <volume>292</volume>: <fpage>640</fpage>–<lpage>651</lpage>.</citation>
</ref>
<ref id="bibr101-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parker</surname><given-names>M.</given-names></name>
<name><surname>Mittleman</surname><given-names>M.</given-names></name>
<name><surname>Waksmonski</surname><given-names>C.</given-names></name>
<name><surname>Sanders</surname><given-names>G.</given-names></name>
<name><surname>Riley</surname><given-names>M.</given-names></name>
<name><surname>Douglas</surname><given-names>P.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Pulmonary hypertension and long-term mortality in aortic and mitral regurgitation</article-title>. <source>Am J Med</source> <volume>123</volume>: <fpage>1043</fpage>–<lpage>1048</lpage>.</citation>
</ref>
<ref id="bibr102-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pokreisz</surname><given-names>P.</given-names></name>
<name><surname>Vandenwijngaert</surname><given-names>S.</given-names></name>
<name><surname>Bito</surname><given-names>V.</given-names></name>
<name><surname>Van den Bergh</surname><given-names>A.</given-names></name>
<name><surname>Lenaerts</surname><given-names>I.</given-names></name>
<name><surname>Busch</surname><given-names>C.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice</article-title>. <source>Circulation</source> <volume>119</volume>: <fpage>408</fpage>–<lpage>416</lpage>.</citation>
</ref>
<ref id="bibr103-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Reindl</surname><given-names>I.</given-names></name>
<name><surname>Wernecke</surname><given-names>K.</given-names></name>
<name><surname>Opitz</surname><given-names>C.</given-names></name>
<name><surname>Wensel</surname><given-names>R.</given-names></name>
<name><surname>Konig</surname><given-names>D.</given-names></name>
<name><surname>Dengler</surname><given-names>T.</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Impaired ventilatory efficiency in chronic heart failure: possible role of pulmonary vasoconstriction</article-title>. <source>Am Heart J</source> <volume>136</volume>: <fpage>778</fpage>–<lpage>785</lpage>.</citation>
</ref>
<ref id="bibr104-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosario</surname><given-names>L.</given-names></name>
<name><surname>Stevenson</surname><given-names>L.</given-names></name>
<name><surname>Solomon</surname><given-names>S.</given-names></name>
<name><surname>Lee</surname><given-names>R.</given-names></name>
<name><surname>Reimold</surname><given-names>S.</given-names></name>
</person-group> (<year>1998</year>) <article-title>The mechanism of decrease in dynamic mitral regurgitation during heart failure treatment: importance of reduction in the regurgitant orifice size</article-title>. <source>J Am Coll Cardiol</source> <volume>32</volume>: <fpage>1819</fpage>–<lpage>1824</lpage>.</citation>
</ref>
<ref id="bibr105-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenkranz</surname><given-names>S.</given-names></name>
<name><surname>Behr</surname><given-names>J.</given-names></name>
<name><surname>Ewert</surname><given-names>R.</given-names></name>
<name><surname>Ghofrani</surname><given-names>H.</given-names></name>
<name><surname>Grunig</surname><given-names>E.</given-names></name>
<name><surname>Halank</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2011a</year>) <article-title>[Right heart catheterization in pulmonary hypertension]</article-title>. <source>Dtsch Med Wochenschr</source> <volume>136</volume>: <fpage>2601</fpage>–<lpage>2616</lpage>.</citation>
</ref>
<ref id="bibr106-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rosenkranz</surname><given-names>S.</given-names></name>
<name><surname>Bonderman</surname><given-names>D.</given-names></name>
<name><surname>Buerke</surname><given-names>M.</given-names></name>
<name><surname>Felgendreher</surname><given-names>R.</given-names></name>
<name><surname>ten Freyhaus</surname><given-names>H.</given-names></name>
<name><surname>Grunig</surname><given-names>E</given-names></name><etal/>
</person-group>. <italic>et al</italic>. (<year>2011b</year>) <article-title>Pulmonary hypertension due to left heart disease: updated Recommendations of the Cologne Consensus Conference 2011</article-title>. <source>Int J Cardiol 154 Suppl</source> <volume>1</volume>: <fpage>S34</fpage>–<lpage>S44</lpage>.</citation>
</ref>
<ref id="bibr107-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rossi</surname><given-names>A.</given-names></name>
<name><surname>Dini</surname><given-names>F.</given-names></name>
<name><surname>Faggiano</surname><given-names>P.</given-names></name>
<name><surname>Agricola</surname><given-names>E.</given-names></name>
<name><surname>Cicoira</surname><given-names>M.</given-names></name>
<name><surname>Frattini</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Independent prognostic value of functional mitral regurgitation in patients with heart failure. A quantitative analysis of 1256 patients with ischaemic and non-ischaemic dilated cardiomyopathy</article-title>. <source>Heart</source> <volume>97</volume>: <fpage>1675</fpage>–<lpage>1680</lpage>.</citation>
</ref>
<ref id="bibr108-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rudolph</surname><given-names>V.</given-names></name>
<name><surname>Knap</surname><given-names>M.</given-names></name>
<name><surname>Franzen</surname><given-names>O.</given-names></name>
<name><surname>Schluter</surname><given-names>M.</given-names></name>
<name><surname>de Vries</surname><given-names>T.</given-names></name>
<name><surname>Conradi</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Echocardiographic and clinical outcomes of MitraClip therapy in patients not amenable to surgery</article-title>. <source>J Am Coll Cardiol</source> <volume>58</volume>: <fpage>2190</fpage>–<lpage>2195</lpage>.</citation>
</ref>
<ref id="bibr109-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rudski</surname><given-names>L.</given-names></name>
<name><surname>Lai</surname><given-names>W.</given-names></name>
<name><surname>Afilalo</surname><given-names>J.</given-names></name>
<name><surname>Hua</surname><given-names>L.</given-names></name>
<name><surname>Handschumacher</surname><given-names>M.</given-names></name>
<name><surname>Chandrasekaran</surname><given-names>K.</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Guidelines for the echocardiographic assessment of the right heart in adults. A report from the American Society of Echocardiography endorsed by the European Association of Echocardiography, a registered branch of the European Society of Cardiology, and the Canadian Society of Echocardiography</article-title>. <source>J Am Soc Echocardiogr</source> <volume>23</volume>: <fpage>685</fpage>–<lpage>713</lpage>.</citation>
</ref>
<ref id="bibr110-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Saraiva</surname><given-names>R.</given-names></name>
<name><surname>Yamano</surname><given-names>T.</given-names></name>
<name><surname>Matsumura</surname><given-names>Y.</given-names></name>
<name><surname>Takasaki</surname><given-names>K.</given-names></name>
<name><surname>Toyono</surname><given-names>M.</given-names></name>
<name><surname>Agler</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Left atrial function assessed by real-time 3-dimensional echocardiography is related to right ventricular systolic pressure in chronic mitral regurgitation</article-title>. <source>Am Heart J</source> <volume>158</volume>: <fpage>309</fpage>–<lpage>316</lpage>.</citation>
</ref>
<ref id="bibr111-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shan</surname><given-names>X.</given-names></name>
<name><surname>Quaile</surname><given-names>M.</given-names></name>
<name><surname>Monk</surname><given-names>J.</given-names></name>
<name><surname>French</surname><given-names>B.</given-names></name>
<name><surname>Cappola</surname><given-names>T.</given-names></name>
<name><surname>Margulies</surname><given-names>K.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Differential expression of PDE5 in failing and nonfailing human myocardium</article-title>. <source>Circ Heart Failure</source> <volume>5</volume>: <fpage>79</fpage>–<lpage>86</lpage>.</citation>
</ref>
<ref id="bibr112-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simonneau</surname><given-names>G.</given-names></name>
<name><surname>Galie</surname><given-names>N.</given-names></name>
<name><surname>Rubin</surname><given-names>L.</given-names></name>
<name><surname>Langleben</surname><given-names>D.</given-names></name>
<name><surname>Seeger</surname><given-names>W.</given-names></name>
<name><surname>Domenighetti</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Clinical classification of pulmonary hypertension</article-title>. <source>J Am Coll Cardiol</source> <volume>43</volume>: <fpage>5S</fpage>–<lpage>12S</lpage>.</citation>
</ref>
<ref id="bibr113-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Solin</surname><given-names>P.</given-names></name>
<name><surname>Bergin</surname><given-names>P.</given-names></name>
<name><surname>Richardson</surname><given-names>M.</given-names></name>
<name><surname>Kaye</surname><given-names>D.</given-names></name>
<name><surname>Walters</surname><given-names>E.</given-names></name>
<name><surname>Naughton</surname><given-names>M.</given-names></name>
</person-group> (<year>1999</year>) <article-title>Influence of pulmonary capillary wedge pressure on central apnea in heart failure</article-title>. <source>Circulation</source> <volume>99</volume>: <fpage>1574</fpage>–<lpage>1579</lpage>.</citation>
</ref>
<ref id="bibr114-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Szwejkowski</surname><given-names>B.</given-names></name>
<name><surname>Elder</surname><given-names>D.</given-names></name>
<name><surname>Shearer</surname><given-names>F.</given-names></name>
<name><surname>Jack</surname><given-names>D.</given-names></name>
<name><surname>Choy</surname><given-names>A.</given-names></name>
<name><surname>Pringle</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Pulmonary hypertension predicts all-cause mortality in patients with heart failure: a retrospective cohort study</article-title>. <source>Eur J Heart Failure</source> <volume>14</volume>: <fpage>162</fpage>–<lpage>167</lpage>.</citation>
</ref>
<ref id="bibr115-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tandon</surname><given-names>H.</given-names></name>
<name><surname>Kasturi</surname><given-names>J.</given-names></name>
</person-group> (<year>1975</year>) <article-title>Pulmonary vascular changes associated with isolated mitral stenosis in India</article-title>. <source>Br Heart J</source> <volume>37</volume>: <fpage>26</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr116-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tedford</surname><given-names>R.</given-names></name>
<name><surname>Hassoun</surname><given-names>P.</given-names></name>
<name><surname>Mathai</surname><given-names>S.</given-names></name>
<name><surname>Girgis</surname><given-names>R.</given-names></name>
<name><surname>Russell</surname><given-names>S.</given-names></name>
<name><surname>Thiemann</surname><given-names>D.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Pulmonary capillary wedge pressure augments right ventricular pulsatile loading</article-title>. <source>Circulation</source> <volume>125</volume>: <fpage>289</fpage>–<lpage>297</lpage>.</citation>
</ref>
<ref id="bibr117-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tribouilloy</surname><given-names>C.</given-names></name>
<name><surname>Rusinaru</surname><given-names>D.</given-names></name>
<name><surname>Mahjoub</surname><given-names>H.</given-names></name>
<name><surname>Souliere</surname><given-names>V.</given-names></name>
<name><surname>Levy</surname><given-names>F.</given-names></name>
<name><surname>Peltier</surname><given-names>M.</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Prognosis of heart failure with preserved ejection fraction: a 5 year prospective population-based study</article-title>. <source>Eur Heart J</source> <volume>29</volume>: <fpage>339</fpage>–<lpage>347</lpage>.</citation>
</ref>
<ref id="bibr118-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tryka</surname><given-names>A.</given-names></name>
<name><surname>Godleski</surname><given-names>J.</given-names></name>
<name><surname>Schoen</surname><given-names>F.</given-names></name>
<name><surname>Vandevanter</surname><given-names>S.</given-names></name>
</person-group> (<year>1985</year>) <article-title>Pulmonary vascular disease and hypertension after valve surgery for mitral stenosis</article-title>. <source>Hum Pathol</source> <volume>16</volume>: <fpage>65</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr119-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vahanian</surname><given-names>A.</given-names></name>
<name><surname>Baumgartner</surname><given-names>H.</given-names></name>
<name><surname>Bax</surname><given-names>J.</given-names></name>
<name><surname>Butchart</surname><given-names>E.</given-names></name>
<name><surname>Dion</surname><given-names>R.</given-names></name>
<name><surname>Filippatos</surname><given-names>G.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Guidelines on the management of valvular heart disease: The Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology</article-title>. <source>Eur Heart J</source> <volume>28</volume>: <fpage>230</fpage>–<lpage>268</lpage>.</citation>
</ref>
<ref id="bibr120-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Varadarajan</surname><given-names>P.</given-names></name>
<name><surname>Pai</surname><given-names>R.</given-names></name>
</person-group> (<year>2012</year>) <article-title>Prognostic implications of tricuspid regurgitation in patients with severe aortic regurgitation: results from a cohort of 756 patients</article-title>. <source>Interact Cardiovasc Thorac Surg</source> <volume>14</volume>: <fpage>580</fpage>–<lpage>584</lpage>.</citation>
</ref>
<ref id="bibr121-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Whitlow</surname><given-names>P.</given-names></name>
<name><surname>Feldman</surname><given-names>T.</given-names></name>
<name><surname>Pedersen</surname><given-names>W.</given-names></name>
<name><surname>Lim</surname><given-names>D.</given-names></name>
<name><surname>Kipperman</surname><given-names>R.</given-names></name>
<name><surname>Smalling</surname><given-names>R.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study</article-title>. <source>J Am Coll Cardiol</source> <volume>59</volume>: <fpage>130</fpage>–<lpage>139</lpage>.</citation>
</ref>
<ref id="bibr122-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yin</surname><given-names>J.</given-names></name>
<name><surname>Kukucka</surname><given-names>M.</given-names></name>
<name><surname>Hoffmann</surname><given-names>J.</given-names></name>
<name><surname>Sterner-Kock</surname><given-names>A.</given-names></name>
<name><surname>Burhenne</surname><given-names>J.</given-names></name>
<name><surname>Haefeli</surname><given-names>W.</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Sildenafil preserves lung endothelial function and prevents pulmonary vascular remodeling in a rat model of diastolic heart failure</article-title>. <source>Circ Heart Failure</source> <volume>4</volume>: <fpage>198</fpage>–<lpage>206</lpage>.</citation>
</ref>
<ref id="bibr123-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Yock</surname><given-names>P.</given-names></name>
<name><surname>Popp</surname><given-names>R.</given-names></name>
</person-group> (<year>1984</year>) <article-title>Noninvasive estimation of right ventricular systolic pressure by Doppler ultrasound in patients with tricuspid regurgitation</article-title>. <source>Circulation</source> <volume>70</volume>: <fpage>657</fpage>–<lpage>662</lpage>.</citation>
</ref>
<ref id="bibr124-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zimpfer</surname><given-names>D.</given-names></name>
<name><surname>Zrunek</surname><given-names>P.</given-names></name>
<name><surname>Roethy</surname><given-names>W.</given-names></name>
<name><surname>Czerny</surname><given-names>M.</given-names></name>
<name><surname>Schima</surname><given-names>H.</given-names></name>
<name><surname>Huber</surname><given-names>L.</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Left ventricular assist devices decrease fixed pulmonary hypertension in cardiac transplant candidates</article-title>. <source>J Thorac Cardiovasc Surg</source> <volume>133</volume>: <fpage>689</fpage>–<lpage>695</lpage>.</citation>
</ref>
<ref id="bibr125-1753944713477518">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Zuern</surname><given-names>C.</given-names></name>
<name><surname>Eick</surname><given-names>C.</given-names></name>
<name><surname>Rizas</surname><given-names>K.</given-names></name>
<name><surname>Stoleriu</surname><given-names>C.</given-names></name>
<name><surname>Woernle</surname><given-names>B.</given-names></name>
<name><surname>Wildhirt</surname><given-names>S.</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Prognostic value of mild-to-moderate pulmonary hypertension in patients with severe aortic valve stenosis undergoing aortic valve replacement</article-title>. <source>Clin Res Cardiol</source> <volume>101</volume>: <fpage>81</fpage>–<lpage>88</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>